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ABSTRACT

SND1 MEDIATED DOWNREGULATION OF PTPN23 IN HEPATOCELLULAR
CARCINOMA

By Nidhi Jariwala, MS

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science

Virginia Commonwealth University, 2014.

Advisor: Dr. Devanand Sarkar, M.B.B.S., Ph.D.
Associate Professor, Department of Human and Molecular Genetics
Blick Scholar
Associate Scientific Director, Cancer Therapeutics
VCU Institute of Molecular Medicine
Massey Cancer Center

Staphyloccocal nuclease domain containing protein 1 (SND1) is identified as an oncogene in
multiple cancers, including hepatocellular carcinoma (HCC). SND1 regulates gene expression at
transcriptional as well as post-transcriptional level and mediates molecular pathways that
culminate into carcinogenesis. SND1 is a component of RNA-induced silencing complex (RISC)
and functions as a nuclease for RNAi-mediated mRNA degradation. On the other hand SND1

also binds to specific mRNAs, increasing their stability and hence expression. The aim of the
present study is to identify mRNAs to which SND1 binds and modulates them either by
degradation or increasing stability which might facilitate promotion of HCC by SND1. We
performed RNA immunoprecipitation followed by RNA sequencing (RIP-Seq) using anti-SND1
antibody and human HCC cell line QGY-7703. More than 350 mRNAs were identified to be
interacting with SND1, of which Protein tyrosine phosphatase non-receptor 23 (PTPN23) was of
particular interest, since PTPN23 has been identified to be a tumor suppressor and its role in
HCC has not been studied. We document that SND1 can bind to PTPN23 mRNA and induce its
degradation. There is an inverse correlation between SND1 and PTPN23 levels in human HCC
cell lines and PTPN23 level is downregulated in HCC. Our study thus identifies a novel
mechanism by which SND1 promotes hepatocarcinogenesis and identifies PTPN23 as a potential
tumor suppressor in HCC. Further studies need to be performed to explore the relationship of
these two molecules in in vivo models and to develop PTPN23 overexpression as a potential
therapeutic approach for HCC.

CHAPTER 1

Role of Staphylococcal Nuclease Domain Protein 1 (SND1) in cancer

1

Cancer is a highly aggressive disease characterized by interplay of mutations that
cause cellular transformation and abnormal cell growth. Over the years, state-of-the-art
studies have provided great insights into the pathogenesis of this highly complex disease.
Cancer is now well defined by six hallmarks – sustained proliferative signaling, evasion
of growth suppressors, invasion and metastasis, replicative immortality, angiogenesis and
resistance to apoptosis (1). Change in expression patterns of any gene controlling these
pathways initiate tumorigenesis that has the potential of malignancy. With increasing
number of mutations being identified each day, that play a role in cancer development,
molecular understanding of this disease gets more complicated. Further adding to the
complexity is the effect of environmental factors in disease pathogenesis at each stage.
Mutations arising in cells are mainly governed by genetic predisposition to changes in
DNA structure, stability and expression, epigenetic changes and environmental factors
(2). Epigenetic variations broadly include methylation pattern, microRNA expression
disorders and chromatin organization (2). Diversity in cancer is not just restricted to the
factors leading to cancer development, but is also observed within tumor
microenvironment – broadly classified as inter-tumor heterogeneity and intra-tumor
heterogeneity (2). With the advent of science, the molecular changes, which are
responsible for such alterations are being identified as potential therapeutic targets.
Hepatocellular carcinoma, neoplasm arising in primary hepatocytes of liver is a
highly aggressive primary liver cancer. It has a very high mortality and morbidity rate,
ranking 3rd in cancer related deaths. Liver plays a primary role in metabolism and hence
HCC is closely associated to metabolic pathways, especially lipid metabolism. It is well
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known that majority of the HCC incidences are secondary to cirrhotic liver. A general
understanding about HCC development is aptly described in following figure (3).
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Figure 1.1Progression from Liver Injury to HCC. Molecular changes as liver injury progresses to
inflammation and culminates into hepatocellular carcinoma

Ramakrishna et. al.,Liver Cancer, 2013

Inflammation has been long known to precede carcinogenesis, and is now considered one
of the critical hallmarks of cancer (1). Viral infection, microbial invasion by breach in
liver-gut barrier, alcohol abuse or nonalcoholic steatohepatitis (NASH) are most
commonly observed molecular events that trigger inflammatory response, leading to liver
cirrhosis which culminates into HCC. Necroinflammation and telomere shortening have
also been reported to cause cell senescense and associated with onset of tumorigenesis,
respectively (3). NF-κB- STAT3 inflammatory network is critical for progression of
chronic inflammation of hepatic tissue to HCC (3). Proinflammaory molecules such as
IL6 cause increased activation of STAT3 signaling, subsequently leading to cellular
transformation (3). Relevance of SND1 in this network and eventual development of
HCC, is discussed in detail later. Though significance of chronic inflammation with HCC
development and progression has been well established by multiple studies, detailed
molecular understanding of this vital association is not reported.
Staphylococcal nuclease and tudor domain containing 1 (SND1) is known to be
involved in transcriptional activation, RNA splicing, editing and stability, and RNAi
function (4-11). These processes are relevant for regulation of gene expression. SND1 is
predicted to manifest a dynamic role modulating multiple molecular networks that
control gene expression. SND1 has been proven to play a crucial role in transcriptional
regulation of several genes important for tumorigenesis (6, 12-14). Structural analysis has
confirmed that the protein functions include nucleic acid interaction along with protein –
protein interactions (4). Several studies have illustrated the significant association of
SND1 with different types of cancers, including breast, prostate, colorectal and liver
cancer. It is overexpressed in these cancers and known to promote manifestation of
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aforementioned hallmarks of carcinogenesis (15). The present review provides a
comprehensive description of the functional aspects of SND1 that are relevant to cancer
development and progression.
SND1 protein structure
Human SND1 gene was assigned to chromosome 7q31.3 band location employing
restriction fragment and fluorescence in-situ hybridization (FISH) analyses (16).
Genomic gain in 7q, especially 7q31, has been demonstrated in prostate, renal and
colorectal carcinoma (17-20). SND1 is overexpressed in prostate and colorectal
carcinoma and genomic amplification might be an underlying mechanism for this
overexpression (21-23).
Human SND1 is a 910 a.a. containing 100kDa protein with highly conserved
domains, observed as low as Caenorhabditis Elegans in evolution. SND1 comprises of
tandem repeats of four nuclease (SN) domains and a fifth domain containing fusion of
Tudor and partial nuclease domains (TSN) (Fig. 1.2). Both, SN domain as well as Tudor
domains have been reported to be involved in protein – protein interactions. The nuclease
domains share 20% - 30% sequence homology amongst each other.(4) These domains
have been well characterized and found to be structurally related to staphylococcal
nuclease (SN) domains (4). These are thermo nucleases that hydrolyze DNA and RNA in
a calcium dependent manner (4). However, hydrophobic cluster analysis shows that the
SN domains of SND1 lack the specific amino acid residues involved in calcium
dependent catalytic activity (4). SN domains are included in the oligonucleotide/
oligosaccharide binding (OB) fold superfamily, which comprises of a large number of
proteins, involved in nucleic acid binding (4). OB fold proteins are critical for DNA
6

replication, DNA recombination, DNA repair, telomeric maintenance and cold shock
response (24). OB fold domains range from 70-150 a.a in length and comprise of variable
loops between conserved secondary domains (24). Other than Staphylococcal Nucleases,
OB fold is also observed in bacterial enterotoxins, nucleic acid binding proteins and
inorganic pyrophosphates (24). Many of the proteins in OB fold family, lack catalytic
activity but carry out several other functions, such as transcriptional activation or
repression, chromatin modification and DNA repair (4, 24). Tudor domains are highly
conserved domains across eukaryotic species and studied in great detail employing
Drosophila model system (25). Tudor domain containing proteins are involved in DNA
interactions, specifically in epigenetic regulation, gene expression as well as snRNP,
miRNA and piRNA biogenesis (25). The presence of these versatile SN and Tudor
domains confer upon SND1 its diverse multifunctional properties. Below is a
representation of SND1 protein structure.
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Figure 1.2 SND1 protein structure. SND1 protein structure comprises of four
Staphylococcal nuclease domains and a single fusion domain, from N terminus to Cterminus. The fusion domain consists of Tudor motif and SN motif. Both, SN domain as well
as Tudor domains have been reported to be involved in protein – protein interaction

Regulation of SND1 expression
The isolated 5’- flanking regulatory region of human SND1 gene spans more than
3.8 kb, including transcription start site and translation initiation codon (26).
Bioinformatics analysis revealed presence of putative binding motifs for NF-κB, Sp1 and
NF-Y transcription factors (26). The core promoter region does not contain TATA box,
but is rich in CpG islands to form pre-initiation transcription complex (26). The lack of a
TATA box, an initiator sequence for transcription is complimented by presence of
CCAAT box in reverse orientation i.e. ATTGG at position -61 and -28 (26). The CCAAT
box and a GC box, at -48, act as positive regulatory elements for SND1 expression (26).
Inverted CCAAT sequences are often binding targets for NF-Y transcription factor (27).
Luciferase assays with promoter deletion mutants show that -274 to -112, containing
potential binding sites for NF-κB and Sp1 are crucial for SND1 expression (26).
Interaction of NF-κB, Sp1 and NF-Y with the SND1 promoter was also detected by
chromatin immnunoprecipitation (26). Mutation in GC box or CCAAT box reduced
SND1 expression by 55-75%. As expected, TNFα treatment induced NF-κB mediated
SND1 transcription, thereby suggesting the functional role of NF-κB in SND1
transcription regulation (26). The fact that NF-κB regulates SND1 transcription
underlines the significance of this interaction in inflammation. Indeed, under proinflammatory conditions, there is an induction in NF-κB levels and activity, which in turn
upregulates SND1 expression. Considering the supporting literature on pro-oncogenic
properties of SND1, it can be speculated that Nf-κB mediated upregulation of SND1 is
instrumental in progression from inflammation to carcinogenesis.
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Promoter regions of human, mice and rat SND1 gene show about 80-85%
sequence homology (26). Similar findings have been observed in promoter analysis of rat
homologue of SND1, p102 (27). Putative binding sites for CCAAT/ enhancer binding
protein (C/EBP), STATs and upstream stimulatory factor (USF) were identified (27). NFY binds at the CCAAT box (-370, -366) whereas the GC rich regions were identified as
putative Sp1 binding sites (27). DNA elements that matched the consensus binding
sequences for liver specific transcription factors, such as HNF-4 were also found (27),
suggesting that SND1 might be differentially expressed in tissue specific manner.
Fashe et. al investigated cellular localization and tissue specific expression of
SND1 in mice. With an exception of muscle tissues, SND1 is ubiquitously expressed in
mice and the expression patterns are mostly consistent with that reported in humans (28).
SND1 is strikingly upregulated in active secretory organs including pancreas, liver and
mammary glands (28). Different studies have reported upregulated levels of SND1 in
lipid droplets of milk secreted by mammary epithelial cells of mouse and cow (28, 29).
SND1 levels were higher in exocrine pancreatic cells as compared to endocrine cells (28).
SND1 is lower than in hepatocytes, however, it is more highly expressed in sinusoid
endothelial cells (28). Actively proliferating cells such as crypts of Lieberkuhn and basal
keratinocytes of skin and hair follicle show high SND1 protein levels compared to more
differentiated or terminally differentiated cells in the same tissue (28). SND1 protein
levels are much higher in spermatogonial cells than in spermatocytes and Sertoli cells
(28). There is no protein detected in terminally differentiated spermatids and mature
spermatozoa (28). In ovary, SND1 levels are high in follicular cells compared to that in
stromal cells. There is no SND1 protein in oocytes (28). SND1 protein levels are
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moderately expressed in human brain tissue, in neuronal as well as glial cells. In mice
kidney, SND1 is comparatively more highly expressed in endothelial cells of Bowman’s
capsule than podocytes and mesangial cells (28). It is also expressed in bronchiolar
epithelium, alveolar cells and pneumocytes of lung (28). Within gastrointestinal system,
SND1 is expressed in ileum, deuodenum and colon. Lower SND1 levels were observed
in more differentiated cells like villi and Paneth cells in ileum and absorptive cells of
colon (28). Overall, SND1 is overexpressed in rapidly proliferating or precursor cells and
downregulated in terminally differentiated cells. SND1 is upregulated in T-cells and colocalizes with CD3, as observed in lymphoid organs (28). Also, SND1 is not expressed in
macrophages, in lymphoid organs as well as tissue residing macrophages like Kuppfer’s
cells in liver and alveolar macropahges in lungs (28). Further, SND1 levels in the red
pulp of spleen are higher than that in white pulp (28). Differential expression of SND1 in
T lymphocytes and macropahges suggests a potential role of SND1 in regulating
immunity (28).
Functions of SND1: regulation of transcription
SND1, also called TudorSN or p100, was first identified as a transcriptional coactivator in an attempt to identify proteins interacting with Epstein Barr Nuclear Antigen
(30). EBNA2 specifically activates transcription of genes that mediate B lymphocyte
transformation (30). Along with known interacting factors such as TFIIB, TFIIH and
TAF40, SND1 specifically interacts with EBNA2 acidic domain (30). This interaction is
mediated by SND1 - TFIIE interaction such that SND1 acts as an adapter protein between
EBNA2 and the transcriptional machinery (30). Pim kinases, found to be up regulated
during Epstein Barr Virus infection, also interact with SND1 and mediate cellular
11

transformation by cooperating to enhance c-Myb activity (10). Pim-1 has been shown to
phosphorylate SND1 and forms a stable complex, leading to an induction in c-Myb
activity (10). Ectopic expression of Ras and Pim-1 also induced Myb responsive genes,
since c-myb is a downstream target in this signaling cascade (10). This research study
thus revealed that SND1 is a vital link in Ras and Pim-1 mediated induction of c-Myb
(10). Lack of SND1 or dominant negative alleles of SND1 failed to cause an induction in
c-Myb activity (10). c-Myb is linked to proliferation and differentiation, and also known
to mediate cellular transformation. Hence, role of SND1 in regulating c-Myb expression
via Ras or Pim-1 is significant to understand its functional impact in oncogenesis.
Another important class of transcription factors that are known to interact and
cooperate with SND1 is Signal Transducers and Activator of Transcription i.e. STATs (6,
31-33). STAT proteins are sequestered to Janus kinases (JAK), which upon stimulation
by cytokines like IFN-γ, undergo phosphorylation (31). Phosphorylation of STAT
proteins and subsequent dimerization leads to nuclear localization where it activates
transcription of target genes (31). Constitutive activation of JAK-STAT pathway has
been implicated in many cancers (31). There are seven STAT proteins, which share
structural and functional homology. Of these, SND1 is known to act as a transcriptional
co-activator for STAT5 and STAT6. STAT5 co-immunoprecipitates with SND1,
confirming the protein –protein interaction, but does not affect the phosphorylation status
of STAT5 (32). Interaction with STAT5 is mediated via SN as well as Tudor domains of
SND1 whereas for STAT6 – SND1 interaction involves only SN domains. SND1 acts as
an adapter molecule, allowing functional bridging between CREB binding protein (CBP)
and STAT6 (33). It interacts with D3-D4 domain of CBP and STAT6 transactivation
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domain (TAD). Histone Acetylase Activity of CBP is stimulated by SND1, thereby
allowing transcriptional activation (33).
A recent study in breast cancer model illustrated that SND1 significantly interacts
with promoter regions of several genes in TGFβ signaling pathway, including Smad1-4
and TGFβ (14). We have shown that SND1 up regulation is also correlated with TGFβ
signaling in HCC, as described later (34).

Post-transcriptional regulation of gene expression
Regulation of RNA-induced silencing complex (RISC) activity
Post-transcriptional regulation of gene expression can be mediated by several
mechanisms including nucleocytoplasmic localization, mRNA stability, mRNA
processing and translation. SND1 functions as a nuclease in RNA-induced silencing
complex (RISC) that plays a significant role in modulation of gene expression at a posttranscriptional level (35). Our studies have shown that Astrocyte elevated gene-1 (AEG1), an important oncogene, in association with SND1 and other proteins, forms a stable
RISC complex (8). RISC incorporates one strand of a small interfering RNA (siRNA) or
microRNA (miRNA) and uses the siRNA or miRNA as a template for recognizing
complementary mRNA. Argonaute proteins are activated in RISC when a complementary
mRNA is identified which then cleaves the mRNA. SND1 functions as a nuclease in
RISC along with the Argonaute proteins while AEG-1 functions as a scaffold protein for
proper assembly of this complex. Both SND1 and AEG-1 are overexpressed in multiple
cancers and together they facilitate functions of oncogenic miRNAs (onco-miRNA).
13

Indeed RISC activity in cancer cells was found to be higher than that in normal cells (8).
The increased activity of onco-miRNAs leads to increased suppression of their target
tumor suppressor genes. In HCC cells it was documented that overexpression of AEG-1
or SND1 resulted in decreased expression of several tumor suppressor genes that are
targets of oncomiRNAs, e.g., PTEN which is a target of miR-221 and miR-21; CDKN1C
(p57), target of miR-221; CDKN1A (p21), target of miR-106b; SPRY2, target of miR-21
and TGFBR2, target of miR-93 (8). The reverse finding was observed upon knockdown
of SND1 or AEG-1 (8). These findings suggest that increased RISC activity conferred by
SND1 and AEG-1 might contribute to the carcinogenic process (8).
In pancreatic cancer, synaptogamin-11 interacts with RISC via SND1 binding
(36). It is hypothesized that this protein is the missing link between membrane trafficking
and miRNAmediated gene regulation (36). Synthesis of mature mir17-92 cluster is also
inhibited by SND1 protein, thereby affecting several downstream target genes (37).
Regulation of mRNA stability
SND1 interaction with mRNA transcript can be independent of the RISC. Studies
show that SND1 interacts with 3’UTR of angiotensin II type 1 receptor (AT1R), a G
protein coupled receptor mediating the action of angiotensin (9). Here, SND1 increases
mRNA stability and translational efficiency by increasing AT1R mRNA half-life,
resulting in elevated protein levels (9). A recent finding shows that SND1 and AT1R
mRNA colocalize in stress granules followed by oxidative stress and SND1 is required
for efficient protein – RNA aggregation (38). These findings imply that SND1 increases
stability of specific mRNAs, crucial for cellular stress response (38). Using HCC cell
lines, we have demonstrated that SND1-mediated increased activity of AT1R activates
14

TGFβ signaling cascade thereby promoting epithelial-mesenchymal transition (EMT) and
increase in migration and invasion (34). Studies have also established interaction of
SND1 and Dengue virus 3’UTR, leading to increased viral replication (39). It needs to be
studied whether SND1 has similar role in promoting replication of Hepatitis B or C
viruses (HBV or HCV), the most common cause of HCC.
Regulation of mRNA splicing
Splicing is an important post transcriptional event, involved in excluding the noncoding intronic regions of mRNA transcript and thereby allowing translation of exonic
regions into a functional polypeptide (40). A large macromolecular complex, driven by
several proteins is required for this processing. Splicing is tightly regulated and
functionally coupled with transcription (40). Because differential regulation of genes
influencing cell growth and proliferation are critical for carcinogenesis, splicing is
speculated to play a vital role in establishing pathogenesis (41). Spliceosome complex
comprises of five major small ribonucleoprotein – U1, U2, U4/U6 and U5 along with
several small non-snRNPs (42). It has been shown that SND1 interacts with U5
component of spliceosome and other non-snRNPs (42). Immunoprecipitation studies with
GST-TSN fusion protein (lacking SN domains) and GST-SN fusion protein (lacking TSN
domain) demonstrated that this interaction is specifically via TSN domain (42). In vitro,
exogenously added SND1 accelerated the kinetics of spliceosome assembly, detected in
terms of a ligated mRNA product, in a dose-dependent manner.(42) However, no
difference was observed in the amount of splicing products with or without SND1 (42). It
was demonstrated that SND1 improved the efficiency of pre-spliceosomal Complex
assembly and accelerated the formation of complex B and complex C (42).
15

Alternative splicing, observed in eukaryotes, allows translation of multiple
polypeptides from the same gene transcript by selection of specific exons to be included
in the processed mRNA (40). Recent reports have shown that deregulation of alternative
splicing is associated with cancer development and progression (41). Studies have shown
SND1 to play a major role in this biological process. SND1 is identified as an interacting
partner for SAM68, a pro oncogenic RNA binding protein that is up regulated in prostate
cancer and supports cellular proliferation (40). SAM68 is involved in alternative splicing
of CD44, specifically favoring inclusion of exon v5 of this gene (40). Inclusion of
variable exons (v5) in CD44 mRNA is correlated with cancer development in prior
studies (40). Authors observed that SND1 is a positive regulator of the alternative
splicing of CD44 via SAM68. Knocking down SND1 inhibited inclusion of upstream
variable exons (v4, v5 and v7) but that of the downstream variable exons (v8-v10) and
constitutive exons was not affected (40). These findings suggest that SND1 co-ordinates
transcriptional and post-transcriptional events for regulation of gene expression. Future
studies focused on splicing activity of SND1 might provide insights into molecular events
governing malignancy.
Regulation of RNA editing
Adenosine deaminase (ADAR) proteins function in RNA A-to-I editing in which
it deaminates Adenosine to Inosine which is read as guanosine on an mRNA transcript.
Such processes regulate protein translation by functionally changing the mRNA sequence
(11). This post-transcriptional regulation also plays a role in gene expression and miRNA
processing (11). Interestingly, ADAR protein expression is tightly regulated during
embryogenesis, it is highest in the oocytes and zygote and diminished in the embryo
16

stages.(11) A strong correlation was observed between ADAR and SND1 levels during
mouse fertilization.(11) While ADAR marks hyperedited transcripts, SND1 is
responsible for degradation of hyper-edited mRNA transcripts as well as miRNA
precursors (11). The data suggests that SND1 and ADAR1 are functionally synchronized
in A-to-I editing and eliminate most miRNA precursors, progressively from oocyte to
zygote (11). However, this function is prohibited during embryogenesis. Thus SND1
plays a crucial role in early stage embryogenesis and cell differentiation (11). Analysis of
a SND1 knockout mouse will provide insights into the role of SND1 in regulating gene
expression during developmental stage.
SND1 and stress response
SND1 plays a key role in cellular stress response via stress granule formation
(43). Several environmental stimuli can be stressful for cellular growth. In response to
such stimuli, cells undergo reprogramming in gene expression that allows cell survival
(43, 44). Initial studies illustrated that SND1 is a component of the cytoplasmic stress
granules and SN domain is crucial for this function (43, 44). SND1 interacts with Ras
GTPase Activating Protein SH3 Domain Binding Protein (G3BP) and Adenosine
deaminase (ADAR1). While G3BP has been shown to be essential for assembly of stress
granules(43), ADAR1 has been linked to apoptosis and stress response (44). ADAR1
levels are also induced by interferon and its deficiency causes defective haematopoesis
(44). Such studies implicate ADAR1 in cell survival and immune response towards
stress. SND1 was found to directly interact with ADAR1. These proteins colocalized
within cytoplasmic stress granules following oxidative stress, heat shock or interferon
induction (44). Knock down of SND1 prohibited assembly of smaller stress foci into
17

larger granules, emphasizing its role in this cellular function (43). These studies need to
be extended into in vivo models to confirm the essential role of SND1 to cope with stress
responses.
Regulation of cell cycle and cell division
SND1 is shown to be an essential protein in the normal programmed cell death, a
process mediated by caspases (45). SND1 is cleaved by caspase 3 during drug-induced
apoptosis. A non-cleavable SND1 mutant increased cell viability and knocking down
SND1 promoted drug-induced apoptosis in HeLa cells (45). Incubation with caspases
completely blocked RNase activity of SND1 indicating that SND1 enzymatic activity is
required for maintaining cell viability or protection from apoptosis (45).
Oncogenic functions of SND1
Role of SND1 in Hepatocellular Carcinoma (HCC)
HCC is the primary liver malignancy, characterized by a highly aggressive form
of cancer. In most cases, HCC develops from a preexisting condition, such as liver
cirrhosis, nonalcoholic steatohepatitis or viral hepatitis infection (3). It is the fifth most
common cancer and ranks third in cancer related deaths worldwide (34). Current
management options include surgical resection, tumor ablation and embolization, though
there is virtually no cure for this cancer. Molecular approaches such as multikinase
inhibitor Sorafenib help to moderately increase the survival of HCC patients. To curb the
increasing mortality rate, there is an urgent need for identification of potential therapeutic
targets that can be employed for translational applications.
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Studies

demonstrate

multiple

ways

by

which

SND1

contributes

to

hepatocarcinogenesis. Immunohistochemical analysis has demonstrated that SND1 is
overexpressed in a high percentage of HCC patients and SND1 levels correlate with HCC
stages (8). Stable clones of human HCC cells, with either overexpression or knockdown
of SND1, in nude mice xenograft studies confirmed the positive role of SND1 in
regulating cell viability and growth (8). Since SND1 is also an integral component of
RISC complex, we investigated if RISC activity correlated with HCC development.
Increased RISC activity was observed in HCC cell lines compared to normal hepatocytes,
which consequently led to increase down regulation of tumor suppressors via RNA
interference (8). As pointed out earlier, SND1 interacts and co-operates with AEG-1 to
form RISC along with other known RISC proteins and inhibition of SND1 activity
diminished AEG-1 activity (8). SND1- AEG-1 interaction was first established in our
study aimed at identifying interacting partners of known oncogene, AEG-1 (46). Further
investigation established that increased SND1 protein levels trigger a cascade of
molecular events that promote invasion, proliferation, migration and angiogenesis (8, 34,
47). We unraveled a linear pathway in which NF-κB activation by SND1 augments miR221 levels (47). As a result of this interaction and increase in miR221, Angiogenin and
CXCL16 protein expression was upregulated and was observed to promote angiogenesis
(47). Analysis of global gene expression profiles of SND1 knock down HCC clones
identified 123 genes drastically down regulated, many of which are in TGFβ signaling
pathway (34). We documented that increased stabilization of AT1R mRNA by SND1
activates AT1R downstream signaling, such as activation of ERK1/2, culminating in
activation of TGFβ signaling pathway. The TGFβ signaling pathway closely regulates
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EMT (34). Indeed, in vitro analysis demonstrated increased invasion and migration in
SND1 overexpressing clones and viceversa in SND1 knock down clones (34), and
expression of EMT marker proteins, such as N-cadherin, Slug and Snail and Vimentin,
was found to be congruent with our hypothesis (34). A tissue microarray on 50 HCC
cases showed statistically significant correlation between AT1R and SND1 levels further
establishing a causative relationship between SND1, AT1R and TGFβ (34).
Insulin growth factor signaling (IGF) pathways are reported to be deregulated in
HCC and found to be a cause of the aggressive tumorigenesis. Insulin like growth Factor
Binding protein 3, a negative regulator of IGF pathway, was reported to be significantly
over expressed in SND1 knockdown HCC clones (48). Thus SND1 might contribute to
HCC by inhibiting IGFBP3 and promoting IGF-1 activity (48).
SND1 promotes invasion and metastasis in breast cancer
Cancer cells possess the ability to invade circulatory system and establish tumors
in tissues distant from the primary site of tumorigenesis. Angiogenesis enables them to
acquire nourishment and growth factors for constitutive proliferation. Metastatic potential
of a tumor is often a measure of the fatality of the cancer. Metastasis has been long
known to be a major cause of disease relapse and cancer related deaths. More patients
succumb to metastatic malignancy than by the primary cancer (49). An efficient
prognosis and diagnostic tool has not been discovered, in spite of several attempts at
analyzing differential expression patterns in tumorous tissue.
iTRAQ based proteomic analysis on breast cancer metastasis model revealed that
SND1 levels are up regulated in correlation with carcinoma progression (49). This study
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aimed at studying gene signatures in breast cancer metastasis model. Out of the 197
proteins differentially regulated in cancerous tissue as compared to normal tissue, only
those that have not been reported in association with metastasis were shortlisted (49).
This approach helped identify 10 novel proteins significantly associated with metastasis,
employing Mass spectrometry and immunohistochemistry. SND1 was one of these
proteins, deregulated in the breast cancer metastasis model and showed significant
differential expression in normal and breast cancer tissue (49). Immunohistochemical
analysis of a tissue microarray showed up regulation of SND1 in majority of the cases
(49).
AEG-1, also called Metadherin, is a known oncogene, associated with most
oncogenic phenotype such as metastasis, invasion, angiogenesis, chemoresistance and
apoptosis (22). Studies have shown that AEG-1 is associated with poor prognosis in
breast metastasis patients (22). It is involved in oncogenic signaling pathways such as
ERK, NF-κB, Ras and Wnt/β-catenin pathway (22). A study aimed at exploring role of
AEG-1 in breast cancer metastasis, identified SND1 as an AEG-1 interacting protein
(22). Role of SND1 in metastasis was further emphasized based on the global gene
expression profiling of SND1 knockdown clones. The list of gene sets globally enriched
in SND1-expressing control cells versus SND1-KD cells was strikingly dominated by
those involving genes up-regulated in some component of metastatic or oncogenic
signaling (22). Genes such as ANGPTL, ID1 and EREG, known to promote specifically
lung metastasis in breast cancer model, is significantly enriched in this gene set (22).
Experimental lung metastasis study on nude mice with highly metastatic breast cancer
cell line, with SND1 knockdown showed dramatic reduction in pulmonary metastatic
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burden in vivo (22). Though SND1 did not promote invasion, it was found to augment
chemoresistance to cells (22). SND1-KD cells demonstrated sensitivity towards
chemotherapeutic drug induced apoptosis. Microarray data from SND1-KD cells showed
up regulation of KiSS1 gene (22). Reporter assays later confirmed that SND1 directly
down regulates the expression of KiSS1 gene that is known to suppress metastasis (22).
Analysis of clinical data set of breast cancer patients with metastasis revealed that SND1
levels strongly correlated with specifically lung metastasis and metastasis free survival
(22). Thus, SND1 is established to be a pro-metastasis protein. A recent finding shows
significance of AEG-1-SND1 interaction in mammary tumorigenesis (50). AEG-1
knockout cells show reduced tumor initiation and sphere formation in vivo (50). This
effect can be completely rescued by ectopic expression of AEG-1 in these cells (50).
However, knocking down SND1 in these clones completely abolished the rescue effect of
ectopic AEG-1 (50). Knocking down SND1 in AEG-1+/+ cells reduces the sphere
formation in vitro and tumor formation in vivo, resembling the phenotype of AEG-1-/cells (50). Thus SND1 is essential for pro-oncogenic manifestation of AEG-1 in breast
cancer (50).
Early studies have established that SND1 cooperates with c-Myb, a differentiation
and growth factor for immature hematopoetic stem cells and brings about lymphocyte
transformation (10). Studies in breast cancer patients show overexpression of c-myb as
well as SND1 (51). Study aimed at identifying target genes of c-Myb transcription factor
revealed that SND1 promoter is one the target sites of c-Myb (51). There could be a
possible positive regulatory mechanism to maintain levels of c-Myb and SND1 that
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potentially maintains tumorigenesis in breast cancer. Other target genes relevant to
oncogenesis identified by these authors were JUN, CXCR4 and CCNB1 (51).
SND1: an efficient diagnostic marker for Prostate cancer and Colorectal cancer
Studies focused on prostate cancer have identified SND1 as an efficient
diagnostic marker (21). In a study including 174 prostrate cancer patients, SND1 levels
could be correlated with histological grade of the tumor (21). SND1 protein levels were
comparable to alpha-methylacyl-coA racemase (AMACR) protein levels, a currently
employed marker protein for prostate cancer diagnosis (21). Though there were some
cases were SND1 and AMACR protein levels differed, there was robust over expression
of SND1 in tumorigenic tissue (21, 40). It was suggested that multiple protein markers,
including SND1 and AMACR, should be used for better diagnosis of the disease (21).
Knocking down SND1 reduces proliferation of prostate cancer cells, demonstrating the
importance of SND1 in maintaining prostate cancer viability (21). SND1 also promotes
prostate cancer development by positively regulating CD44 alternative splicing, allowing
inclusion of variable exon v5 that is known to be pro-oncogenic (40).
SND1 is also significantly associated with colorectal cancer. A recent genome
wide analysis of methylation patterns in CRC patients revealed a pool of genes that are
differentially methylated in cancerous tissue in comparison to adjacent normal tissue
(52). The study also included tissue from normal, healthy patients with no familial history
of CRC as a control. CpG site located in SND1 gene was identified with highest
discriminative accuracy, highlighting role of this protein in oncogenesis (52). Most of the
hypermethylated CpG sites lied within the SND1 gene regions whereas methylation in
the promoter region of SND1 was observed to be comparatively lower. SND1, along with
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other genes, was thus identified as a potential diagnostic candidate gene (52). Significant
correlation is observed in nodal stage, pathological stage and co-expression of SND1 and
AEG-1 in colon cancer (53). Immunohistochemical analyses of 196 colon cancer cases
establish that cytoplasmic expression of AEG-1 and SND1 protein positively correlates
with tumor grade and cancer progression, but negatively correlates with post-operative
survival of patients (53). The study suggests potential application of these proteins as
prognostic markers for colon cancer (53).
SND1 downregulates Adenomateous Polyposis Coli protein levels by posttranscriptional modification, without altering the mRNA levels of this gene, as reported
in colon cancer (23). APC is a tumor suppressor in colon carcinogenesis and also
associated with maintaining cell polarity and cell-cell adhesion by regulating E-cadherin
localization (23). Loss of APC protein leads to stabilization and subsequent accumulation
of β-catenin by preventing its proteasomal degradation with subsequent loss of contact
inhibition and increased proliferation (23). These findings suggested that SND1 might be
involved in early stage colon carcinogenesis. However, whether miRNAs or RISC is
involved in SND1-mediated downregulation of APC protein remains to be studied.
SND1 in malignant glioma.
Malignant gliomas are the most frequent malignant brain tumor in adults (64). Current
multi-modality therapies include surgery, radiation and chemotherapy, nonetheless the
prognosis of malignant glioma remains extremely poor (65). The rapid growth and highly
invasive nature of malignant glioma, favors its infiltration into surrounding normal brain
parenchyma and facilitates recurrence after therapy (66). This aggressive disease
progression necessitates further understanding of molecular mechanism involved in
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glioma growth and invasion that ultimately will lead to identification of novel therapeutic
targets of translational relevance. Our recent studies suggest that SND1 may provide a
novel target for malignant glioma treatment (20). In this study we found higher SND1
mRNA and protein in human malignant glioma tissue as compared to normal brain. The
Cancer Genome Atlas (TCGA) data showed a similar trend of high SND1 expression in
human astrocytoma and glioblastoma samples as compared to normal brain. Additionally
Rembrandt (Repository for Molecular Brain Neoplasia) data supports the prognostic
significance of SND1 expression in which patients with intermediate levels of SND1
survived longer than patients showing elevated SND1 expression. Overexpression (OE)
and knock down (KD) studies were performed to unravel the functional significance of
SND1 in glioma progression. Overexpression of SND1 in immortalized primary human
fetal astrocytes (IM-PHFA) (low SND1) significantly enhanced invasion and colony
formation as compared to parental IM-PHFA cells. Conversely, when SND1 was
knocked down in multiple glioma cell lines (high SND1), it significantly decreased
invasion and colony formation, both in monolayer and in soft agar. Interestingly, SND1KD primary glioma cells demonstrated enhanced sensitivity towards Temozolomide, an
FDA approved drug used with radiation therapy as a standard of treatment for GBM
patients (67). Knock down of SND1 in malignant glioma cells resulted in a flat-shaped
cells, which stained positive with β-galactosidase, indicating induction of cellular
senescence. Further studies documented a potential involvement of STAT-3 in SND-1mediating glioma invasion and senescence-induced cell death. An intracranial xenograft
study in nude mice using a highly invasive patient-derived malignant glioma cell line,
showed a significant improved survival in SND1-KD group. This was associated with a
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significant decrease in proliferation marker, activated STAT3, and angiogenesis marker
and an enhanced expression of apoptotic marker. The observation that SND1 regulates
several important determinants of glioma progression supports the rationale of using
SND1-inhibition as a means of treating glioma patients.
Specific inhibitors of SND1
BLAST search reveals that SND1 is the only eukaryotic protein with Tudor and
SN fusion domain. Hence, this quaternary fold can be employed for targeted therapeutic
approaches, developing SND1 specific inhibitors. Similar protein domain is observed in
Plasmodium falciparum, a parasite causing malarial infections in humans. Studies with P.
falciparum SND1 have confirmed that SN domain is involved in nuclease activity
whereas Tudor domain carries out the function of RNA binding (15). 3′, 5′ Deoxythymidine bisphosphate (pdTp) is a competitive chemical inhibitor against SNases.
In P. falciparum , it not only blocks the nuclease activity but also inhibits RNA/ protein
interaction of SND1.(15) pdTp inhibited growth of both chloroquine-sensitive and
chloroquine-resistant strains of P. falciparum at a concentration of 100-200 μM of
SND1 inhibitor, suggesting that pdTp might be developed as an anti-malarial drug (15).
Studies performed in our laboratory using multiple human HCC cell lines demonstrated
that pdTp treatment resulted in significant reduction in call viability and colony forming
potential (8). However, this effect was observed at high chemical concentrations, ranging
from 100-200 μM thus rendering it ineffective for clinical applications. Further high
throughput screening assays need to be performed to develop clinically relevant chemical
inhibitors against SND1 enzymatic activity. Employing the C terminus fusion domain of
Tudor SN might prove to be a productive effort in designing targeted molecular therapy.
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CHAPTER 2
An Introduction to Protein Tyrosine Phosphatases
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Significance of kinase- and phosphatase-mediated regulation of cell functions
Kinases and phosphatases are a set of complimentary enzymes responsible for
phosphorylation and dephosphorylation of proteins, respectively, associated with a
multitude of human diseases (1-3). This set of reversible reactions is a common mode of
post-translational modifications of eukaryotic proteins. By changing phosphorylation
status of specific amino acid residues of proteins, these enzymes coordinate signaling
events that determine cellular responses against external or internal stimuli. Several
molecular signaling networks are tightly regulated by a balanced interplay between
kinases and phosphatases. Deregulated function of these enzymes has been suggested to
cause pathophysiologies ranging from autoimmune reaction to carcinogenesis (3, 4).
With emerging discoveries, their role as potential drug targets becomes more evident.
Protein phosphatases have evolved from a wide spectrum of protein families, mainly
categorized by the substrate amino acid residues into four classes. Of these, tyrosine
phosphatases is the largest group of enzymes, encoded by more than 100 genes and
subdivided into four main classes (1). Class I comprises of Dual specificity phosphatases
and tyrosine phosphatases, two main groups of Protein Tyrosine phosphatases (PTPs) (1)
The Dual Specificity enzymes can utilize Serine/ Threonine as well as Tyrosine residues
as their catalytic substrates whereas the classical enzymes show specificity restricted to
Tyrosine residue (1). Serine/ threonine phosphatases exist in vivo in a range of
holoenzymes with variable regulatory or catalytic functional role (1). Physiologically, a
given dual specificity phosphatase demonstrates functional specificity for either of these
amino acid residue (1). The dual specificity enzyme sequence is not well conserved,
demonstrates variability except for the cysteine containing catalytic domain (1). In this
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study, we focus on classical tyrosine phosphatases, described in detail below. Class II
consists of a single low molecular weight phosphatase (4). Yeast cdc25 homologues
make up the Class III whereas drosophila Eya homologs are categorized as Class IV PTP
(4)
Initial evidence suggesting phosphatase activity was encountered while studying
significance of tyrosine phosphorylation in cell growth and signaling (5). These studies
were based on temperature sensitive mutants of SRC oncogene that encodes protein
tyrosine kinase (5). Enzymatic activity observed to counter protein phosphorylation by
kinases was the preliminary evidence of phosphatase activity (5). PTP1A and PTP1B
were the first purified extracts of phosphatases, of which PTP1B was crystallized for
structural analysis (5). Years of investigation later, scientists have deduced the structural
details of this group of proteins. Enzymatic catalysis of these proteins has been studied in
great depth.
Classical PTP structure
PTP structure has been very well characterized, identified by a signature catalytic motif
HC(X)5R (1). The cysteine residue in this active site acts as a nucleophile and is essential
for binding of the enzyme to target phosphate group on the substrate (1). In addition to
large number of genes that encode protein tyrosine phosphatases, further diversity is
contributed by mechanisms such as alternative splicing and post translational
modifications (1). The complex level of diversity and the observed functional
deregulation in several pathophysiologies are suggestive of the crucial role of these
enzymes in cellular signaling. Based on the protein structure and cellular localization,
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classical PTPs can be divided into two major categories – receptor (RPTPs) and nonreceptor type of phosphatases (PTPNs).
Structures of classical tyrosine phosphatases are illustrated in figure below (1).
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Figure 2.1 Classical Tyrosine Phosphatase family and its structural diversity. Structural representation of
receptor and non-receptor classical tyrosine phosphatases

Tonks et. al; Nature Reviews Molecular Cell Biology 7, November 2006

Classical protein tyrosine phosphatase receptor typically comprises of a transmembrane
domain that links the protein to the plasma membrane of cell. This domain is often
attached to an extracellular domain, which is receptive to external signaling via specific
molecules. It regulates cell signaling via substrate protein tyrosine de-phosphorylation,
triggered by receptor – ligand interaction. The cytoplasmic chain consists of tandem
repeats of the PTP domain (1). However, in most classical receptor type enzymes, the
catalytic function is carried out by the PTP domain proximal to membrane whereas the
distal domain has been proven critical for intracellular protein – protein interactions (1, 6,
7). Several of the enzymes belonging to this class have been associated with cell- cell
adhesion(8) and cell- matrix interactions (1). Dimerization of the protein tyrosine
phosphatases receptor followed by ligand interaction has been implicated in regulation of
enzyme activity (1, 9).
Protein tyrosine phosphatase non receptor type comprises of regulatory units flanking the
enzymatic domain (1). These flanking regions are responsible for substrate specificity
and subcellular localization of the active protein thereby assisting in catalytic dephosphorylation (1). SHP1, PTPN23 (HD-PTP) and PTP1B are some of the most well
characterized non-receptor PTPs. For example, SH2 domain in SHPs directs the protein
towards target substrate tyrosine sites for phosphorylation (10). Similarly, FERM
domains target the PTPs to interface between plasma membrane and cytoskeleton (11)
and BRO1 domain targets proteins to endosomes (12). Apart from stringent subcellular
targeting, these PTPs show high sequence identity and non-redundant functional
specificity (5).
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PTP function and regulation of enzymatic activity
PTPs are known to negatively regulate tyrosine phosphorylation, thereby terminating the
signaling cascade. This enzymatic activity is essential to balance phosphorylation
dependent molecular signaling, in order to maintain cellular physiology. With the
advances in science, significance of these proteins has been emphasized in regulation of
cellular metabolism and cell cycle. General catalytic reaction of PTPs is aptly described
in figure 2.2. Cysteine residue in the catalytic domain functions as a nucleophile and the
attacks the phosphate group on substrate tyrosine residue to break the phosphorus–
oxygen bond. The aspartate in the WPD loop acts as a generate acid and donates a proton
to the dephosphorylated tyrosine (4). This generates an unstable phosphocysteine
intermediate and the dephosphorylated substrate is released (4, 13). The phosphocysteine
intermediate is cleaved via hydrolysis by the aspartate residue and results in the release of
free phosphate (4).
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Figure 2.2. Enzymatic catalysis by classical tyrosine phosphatases. The cysteine (Cys) residue in
catalytic domain acts as a nucleophile and attacks the phosphate group on substrate, whereas the
Aspartate (Asp) residue behaves as a proton donor to mediate dephosphorylation of the target
protein.

Zhao et al, Oncogene (2014)

Reactive oxygen species have been implicated in altering tyrosine phosphatase mediated
signaling pathways, under normal physiology as well as in cancer cells (1, 14). The
nucleophilic nature of cysteine residue within the active domain renders it susceptible to
reversible oxidation by ROS thereby resulting in inhibition of the enzymatic action (15).
Oxidation of nucleophile, cysteine brings about conformational changes that are nonconducive for substrate binding (15). Several ligand molecules are known to trigger
reversible oxidation of receptor tyrosine phosphatase. For example, insulin, epidermal
growth factor (EGF) and TNFα stimulate oxidation of PTP1B, PTEN and MKPs,
respectively (1). Ligand interaction mediating dimerization of the receptors is also a
proposed mechanism for regulation of receptor PTP activity. Crystallization studies have
elucidated that such dimerization of RPTPs result in reciprocal occlusion of active sites,
thereby inhibiting the enzymatic activity (9). However, only few ligands have been
identified so far, in this context. For example, RPTPζ activity following binding of
pleiotrophin is shown to result in increased phosphorylation of - catenin, a known
substrate of RPTKα (1, 9, 16).
According to current understanding of tyrosine phosphorylation mediated signaling, an
external physiological stimuli triggers inhibition of the tyrosine phosphatases, thereby
allowing amplification of the tyrosine phosphate mediated signaling (1). Loss of stimuli
results in activation of the phosphatase and subsequent termination of the signaling
pathways (1). Inhibition of phosphatase activity is complimentary to kinase activity that
promotes tyrosine phosphorylation, and downstream signaling. Hence, an optimum
balance between phosphatase and kinase activity is crucial for maintenance of normal
physiology.
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Identification of HD-PTP or PTPN23
First study that identified PTPN23 as HD-PTP (His domain containing PTP) was aimed
at identifying phosphatases that play critical role in hypertrophy in cardiomyocytes.
Among the 16 target phosphatases, HD-PTP was a novel discovery. Though the protein
was observed to be ubiquitously expressed, distinctly high levels were detected in rat
neonatal cardiomyocytes (17). PTPN23 is localized within cytoplasm and protein
localization was found to be independent of the PTP domain (17, 18). Preliminary mRNA
sequence analysis established the presence of a BRO1 domain, a yeast signaling protein,
on the N terminus of translated protein (17). The identified HD-PTP cDNA sequence
showed a variant from the generic catalytic site sequence of most PTP’s identified to
date. Specifically, serine residue was observed to be replaced by an alanine residue (17).
However, the overall sequence was observed to be in synchrony with that of the
phosphatases. This study also demonstrated that PTPN23 inhibits Ha-Ras mediated
cellular transformation. When PTPN23 was overexpressed in Ha-Ras expressing cells,
foci formation was significantly reduced by 33% (17). This was the first evidence
implying a tumor suppressive role of PTPN23.
PTPN23 genomic cDNA sequence was first isolated in an attempt to characterize human
genomic sequences that promoted anchorage independent growth of cells. These
sequences were derived from B – cell lymphoma (18). Southern hybridization with
human genomic DNA probe identified nine repeat regions (18). Each of these sequences
was then employed for Northern blot analysis for identification of corresponding mRNA
sequence (18). A common 6kb sequence was identified using three different probes (18).
These probes were than utilized for screening human cDNA library obtained from tumor
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cell line (18). Analyzing the identified mRNA sequence confirmed that the protein
encoded by this gene belonged to the PTP superfamily, later identified to be PTPN23
(18). PTPN23 gene was localized on short arm of chromosome 3, specifically 3p.21.3
(18). This region is observed to be frequently deleted in many cancers including lung,
breast, renal, urogenital and bladder carcinoma (19, 20), further implying PTPN23 as a
tumor suppressor gene. Alterations within the sequence were mostly restricted to the
substrate-binding domain, indicating altered substrate specificity.(18)
PTPN23 structure and expression pattern
Initial bioinformatics analysis revealed that PTPN23 protein is proline rich (17%) and
lacks transmembrane domain as well as a unique localization peptide (17). The N
terminus of PTPN23 also shows 45% similarity with BRO1 domain (17, 18). Literature
confirms that BRO1 domain is homologous with a yeast signaling protein, involved in
mitogen activated protein kinase signaling cascade. Detailed analysis also revealed
presence of two SH-3 binding domains towards the C terminal end of BRO1 domain
(17). This protein sequence was also found to be significantly similar to mouse AIP1, an
apoptosis regulatory protein. The C terminus of PTPN23 carried an amino acid sequence
similar to a known ‘PEST’ protein destabilizing sequence, indicative of a very short halflife of this protein (17, 18). Thus the PTPN23 protein structure can be explained as
follows: a functionally uncharacterized BRO1-like domain (BRO), a histidine-rich
domain (HIS), a classical protein tyrosine phosphatase domain (PTP) and a proteolytic
degradation targeting sequence (PEST motif). Below is representation of PTPN23
structure (21).
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Figure 2.3 PTPN23 protein stricture. PTPN23 comprises of four important domains, from N terminus to C- terminus
- a yeast signaling domain, BRO1, Histidine and proline rich, a catalytic phosphatase domain and PEST domain

F. Ichioka et al., Archives of Biochemistry and Biophysics 2007

Though in vitro biochemical assays indicate a lack of phosphatase activity, an in vivo
loss of PTPN23 mouse models, provides insight into the crucial role of this protein in
mammalian development. PTPN23 gene was disrupted by insertion of β-galactosidaseneomycin- phosphotransferase II (β-geo) DNA sequence (22). Such insertion resulted in
loss of wild-type PTPN23. This protein was found to be essential for mouse
embryological development and loss of 3’region of PTPN23 was embryonically lethal at
E8.5 (22). Expression analysis of WT mouse showed distinct expression of PTPN23 in
neurological tissues of an E9.5 embryo, specifically within neuroepithelial lining of
midbrain, hindbrain, inner side of optic and ottic vescicle and ventricular area of
forebrain (22). At E12.5, PTPN23 expression is more pronounced encompassing more
organs including tongue, heart, gut, common bile duct, precursor stomach, lung, bronchia
and vertebral column (22). With advancing embryonic age, PTPN23 expression was
observed to be more cell-specific, ubiquitous but variable (22). Extended expression
analysis in adult tissues revealed similar pattern, conserved in adulthood as well, although
loss of expression was observed within spleen, heart and muscle tissue (22). Expression
of PTPN23 in adult mammalian skeletal tissue is controversial, with two independent
studies showing distinctly high to low levels of mRNA, respectively (17, 22, 23).
Another study affirms the fact that particularly high levels of PTPN23 are observed in
brain and kidneys of fetal tissue (17, 23). Negligible to very low levels of PTPN23
transcript was detected in liver tissue (17, 23).
In vitro biochemical studies reported that PTPN23 lacks catalytic phosphatase activity,
and the specific amino acid substitution is implicated to be the causative factor (17, 24).
Although, later studies have identified Src Kinase to be a direct substrate of the
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phosphatase activity of PTPN23 (25). At the same time, role of PTPN23 in endosomal
cargo sorting and epidermal growth factor receptor (EGFR) transport to lysosomes is well
documented, apart from its effect in several oncologically relevant cellular functions. It
was observed that RNAi mediated knockdown of PTPN23 caused disruption in recycling
EGFR to lysosomal machinery and accumulation of ubiquitinylated proteins on
endosomal compartments (26).
Mutations in PTP genes are associated with a variety of diseases
Reversible phosphorylation of tyrosine residues of proteins has been studied as a popular
signaling mechanism under physiological conditions. Phosphatases regulate levels of
phosphorylation and their mode of action is well conserved in eukaryotes, highlighting
their significance in normal development and physiology. Research has demonstrated
role of phosphatases in a range of molecular pathogenesis, including developmental
disorders, autoimmune reactions and cancer.(2, 4) Deregulation of phosphatase function
in association with human diseases has been studied in great details.
Loss-of-function as well as gain-of-function mutations in PTP genes have been reported
in reference to human diseases. Several single nucleotide polymorphisms in PTP genes
are shown to be associated with diseases, though underlying molecular mechanisms are
not studied yet. A single nucleotide insertion within the 3’UTR of PTPN1 leads to
increased mRNA stability and subsequent overexpression of PTPB1 protein (27). PTPB1
dephosphorylates and inactivates insulin receptor, thereby increasing insulin resistance, a
trait commonly observed in type 2 diabetes mellitus patients (28). Studies in knockout
mice models have demonstrated that loss of PTPB1 protein confers resistance to high fat
diet induced diabetes and obesity (28) A study has also shown association between a
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polymorphism in PTPN1 intron 6 and body fat distribution and diabetes mellitus type 2
(29). PTPN2 is important in immune regulation and has been identified as a susceptibility
locus in inflammatory bowel disease as well as autoimmune reactions.(2, 4) SNPs in
PTPN2 are associated with autoimmune disorders such as Rheumatoid arthritis (30, 31)
whereas loss of PTPN2 is also observed in a subset of leukemia cases therefore
implicating its role as a tumor suppressor (32). SNPs causing increased expression of
STEP (Striatal enriched protein tyrosine phosphatase), encoded by PTPN5 and expressed
in a brain specific manner, has been associated with increased susceptibility to cognitive
disorders such as hereditary schizophrenia(33) SNP causing reduced PTPN12 expression
is embryonically lethal, so is a gain of function mutation in PTPN11. Similarly, SNP
resulting in partial loss of function of PTPN12 is associated with increased risk of
developing breast cancer (34). A range of mutation in PTPN11 are linked to several
diseases, from autosomal dominant dysmorphic Noonan syndrome to leukemia and
autoinflammatory Lupus erythematosus (35, 36). SNPs in PTPN13 are studied in
association with familial hepatocellular carcinoma, lung carcinoma and colorectal cancer
(37, 38). A SNP in PTPN22 gene (p.R620W) resulting in amino acid substitution
(arginine to tryptophan) is associated with increased risk of autoimmune disorders such
as Graves’ disease and Rheumatoid arthritis (39). Broadly, non-receptor PTPs are
implicated in inflammatory disorders, psychiatric disorders, metabolic disorders such as
type 2 diabetes mellitus and cancer predisposition.
In case of receptor PTP, mutations0 have been linked to a similar array of disorders. For
example, mutations in PTPRA, PTPRC and PTPRD are associated with Schizophrenia,
Severe Combined Immunodeficiency and renal cancer, respectively.(2, 4) These
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comprehensive analyses underline the role of tyrosine phosphatases in maintenance of
cellular functions, its association with human pathologies as well as its significance in
developing therapeutics.
Role of PTPs in cancer
Due to their integral role in cellular signaling, PTPs are strongly suggested to be involved
in cancer development and progression. Early attempts to study role of PTPs in cancer
were focused on colorectal cancer. Research identified deregulation of PTPRT, PTPRF,
PTPRG, PTPN3, PTPN13 and PTPN14 in approximately 26% of the CRC cases (40). A
more recent study has identified PTPRT, PTPRC, PTPRD and PTPRM as tumor
suppressors in head and neck squamous cell carcinomas (41). Detailed information about
PTP mutations in human cancer is now available via high throughput sequencing
analyses. Protein tyrosine phosphatase receptor T (PTPRT) manifests missense mutation
in multiple cancers such as colon, bladder, endometrium, esophagus, head and neck
squamous carcinoma, lung and stomach (40, 41). Mutations resulting in truncated protein
product are also widely observed in human tumors, suggesting a putative tumor
suppression function of this protein (40). Studies on PTPRT knock out mice have shown
early development of carcinogen induced colorectal tumors (42). Loss of PTPRT due to
promoter DNA methylation is also reported in gastric and colon cancers. STAT3
dephosphorylation is proposed to be the underlying signaling mechanism, mediating
tumor suppressive function of PTPR (42).
Genetic deletions and promoter DNA methylation of PTPRD gene, resulting in loss of
phosphatase activity has been observed in multiple cancers, indicating tumor suppressive
function. Mutations in this gene have also been observed in glioblastoma multiforme,
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neuroblastoma, head and neck, lung and colon cancers (43, 44) PTPRD knock out mice
manifest enhanced gliomagenesis whereas overexpression of this protein in colon cancer
cells inhibited migration, implying its role in metastasis (44).
PTPRK, known to promote cell adhesion, migration and proliferation via EGFR
signaling,(45, 46) is frequently mutated in breast, cervical, colon, endometrial and skin
cancers as well as glioma and lymphoma. It is also known to dephosphorylate Her2,
subsequently inhibiting growth of breast cancer cells. Almost 26% of angiosarcoma cases
manifest nonsense or frame-shift mutations in PTPRB gene suggestive of its role as
tumor suppressor (47). Knock out of PTPRB is embryonically lethal, emphasizing the
importance of this protein in angiogenesis and development (48).
PTPRJ has been implicated in breast, colon, pancreatic and thyroid cancer (49-51). Intra(52)injections of PTPRJ conjugated adeno-associated virus suppresses growth of
pancreatic cancer cell xenografts (53). PTPRM inhibits proliferation, invasion and
migration in breast, prostrate and brain tumor (54). Proteolytically cleaved products of
this protein have been observed in tumor samples (55). These fragments are found to
translocate to nucleus, where they are hypothesized to mediate cancer specific functions
(55). Exact molecular mechanisms underlying this hypothesis have not been elucidated.
Among non-receptor PTPs, PTPN11 is a rare PTP to function as an oncogene in juvenile
myelomonocytic leukemia, acute myeloid leukemia . Germ line gain of function mutation
in PTPN11 was first observed in Noonan syndrome cases (52). Contrarily, PTPN11 is
also demonstrated to act as a tumor suppressor in hepatocellular carcinoma by a recent
study. Liver specific knockout of PTPN11 in mouse model resulted in increased
susceptibility to carcinogen-induced HCC (56). PTPN11 is also suggested to be a tumor
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suppressor in metachrondomatosis (57). Loss of function of PTPN11 have also been
implicated in other diseases such as Leopard syndrome (58). At cellular level, it has been
shown to regulate several critical signaling pathways including Jak/Stat, PI3K/AKT,
NFB and Ras-ERK MAPK.
PTP1B, encoded by PTPN1 is overexpressed in ~72% of breast cancer cases (58). Protein
levels of PTP1B are correlated with Erbb2 expression and known to activate c-Src and
Ras signaling (58). PTPN1 is also implicated in tumor suppression, according to genome
wide sequencing. It is mutated in ~20% Hodgkin’s lymphoma and primary mediastinal B
cell lymphoma cases (59). Most of the identified mutations are loss of function, and few
of them are non-sense or missense mutation, parallel with the tumor suppressive function
(59). PTPN1 dephosphorylates insulin receptor and JAK2, thereby negatively regulating
JAK-STAT and PI3K/AKT signaling (28) PTPN1 knockout mice demonstrate delayed
Erbb2 induced breast cancer and decreased lung metastasis (60).
Mutations leading to loss of function of PTPN13 are identified in endometrial, lung, liver,
breast and colorectal cancers (40, 61). In colorectal cancer, PTPN13 is identified as a
substrate of mir200, known to promote EMT. It is also known to interact with Bcr-Abl,
such that Bcr-Abl expression in myeloid progenitor cells up regulated PTPN13 protein
levels and induce apoptosis (62). PTPN13 is known to regulate Adenomatous Polyposis
Coli/ β-catenin pathway and PI3K/AKT signaling. Insulin receptor 1 and Ephrin B1 are
identified PTPN13 substrates whereas phosphorylation of ERK and Her2/Erbb2 is
inversely correlated with PTPN13 expression (63). Negative regulation of PI3K/AKT
pathway via PTPN13 leads to apoptosis in breast cancer cells (64). Epigenetic silencing
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of PTPN13 is observed in non-Hodgkin’s and Hodgkin’s lymphoma, breast, gastric and
hepatocellular carcinoma (61).
PTPN14 is known to regulate -catenin pathway(65), promoting cell adhesion, migration
and cell growth. It was initially identified as a tumor suppressor in breast cancer, where it
was observed to promote anchorage independent proliferation of mammary cells (65).
Currently, it is established that PTPN14 mutations are associated with breast, colon and
endometrium cancers. Point mutation at Y128 residue of p130Cas, a direct substrate of
PTPN14

promotes

migration,

adhesion

and

tumorigenesis

in

colon

(66).

Dephosphorylation of this tyrosine residue results in slower growth of colon cancer
xenograft tumors, reduced migration and colony formation as well as impaired anchorage
independent growth (66). It is also observed to mediate epithelial-mesenchymal transition
via TGFβ pathway regulation.
Significance of non-receptor PTPs in hepatic physiology and function
With increasing evidence emphasizing role of phosphatases and kinases in cellular
functions, there have been some rigorous studies on elucidating role of PTPs in liver
physiology. Liver is a critical link between metabolism and diseases and deregulation of
hepatic functions can result in multifarious effects on normal physiology. Hence,
molecular signaling pathways in liver are very tightly regulated and most of these
mechanisms are dependent on tyrosine phosphorylation.
PTP1B, a non-receptor type PTP, is studied as a negative regulator of insulin receptor
signaling and leptin signaling (67). Phosphorylation of IR is necessary to activate
multiple downstream signaling molecules, such as AKT, mTORC and PI3K via
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phosphorylation of IR substrates (67). PTP1B dephosphorylates IR and thereby inhibits
the subsequent cellular signal transduction (67). Leptin, secreted by white adipose tissue,
is expressed in proportion to body fat mass. It is a key signaling molecule to
communicate with hypothalamus region of brain, in order to regulate fat metabolism (67).
Interaction between leptin and its receptor is known to activate JAK2, thereby affecting
the JAK-STAT signaling network. Dephosphorylation of JAK2 leads to immediate
termination of Leptin signaling. PTP1B has been established to directly mediate
dephosphorylation of JAK2 (67). Hence it is hypothesized that inhibition of leptin
signaling, via PTP1B can be a potential mechanism to promote obesity. This hypothesis
is consistent with the fact that global knock out of PTP1B in mice results in lower
adiposity in spite of a high fat diet (67). Observations were concurrent with increased
brown fat and lower leptin levels in serum. Improved glucose tolerance and lipid profile
was observed in liver specific knock out mice (67). Lack of PTP1B activity also led to
attenuation of endoplasmic reticulum stress (ER), a known cause of obesity (67). There is
convincing evidence that PTP1B is a potential therapeutic target for diabetes as well as
obesity. An independent study revealed that lack of PTP1B also inhibits insulin resistance
and increase in body fat associated with aging (68). Non-significant increase in hepatic
glucose production was observed in aged, PTP1B knock out mice, as opposed to that in
wild type age-matched controls (68). Loss of PTP1B also prohibited hyperinsulinemia
and enlargement of islets indicative of absence of age-related insulin resistance (68).
Accumulation of white adipose tissue is linked to inflammation that can potentially
progress into carcinogenesis. PTP1B knock mice not only demonstrated reduced
adiposity, but also maintained normal tissue specific as well as serum levels of pro-
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inflammatory molecules such as TNFα, indicating absence of inflammation (68).
However, there was a marked increase in the levels of inflammatory molecules in age
matched wild type mice, indicating inflammation in hepatic tissue of wild type mice (68).
Elevated levels of adipose tissue are correlated with steatosis and inflammation in liver.
These conditions give rise to steatohepatitis, culminating into cirrhosis and possibly,
carcinogenesis. Loss of PTP1B also protected the hepatic tissue against obesity induced
steatosis and inflammation by blocking activity of specific kinases (68). Hepatic insulin
signaling was observed to be maintained at normal levels, with advent of age in PTP1B
null mice (68). Under normal physiological functioning, hepatic insulin signaling
declines with age. Insulin resistance, deregulated insulin signaling in liver, increased
accumulation of white adipose tissue, elevated levels of pro-inflammatory molecules
were all congruent with the observed elevation in PTP1B levels of aged mice, as
compared to young ones (68). This was also affirmed by differential expression levels of
negative regulators of insulin signaling pathway, in PTP1B null mice versus age-matched
normal wild type mice (68). Researchers have also established that PTP1B levels are
down regulated in most of the HCC cases. Lower PTP1B levels also correlated with
overall survival rate of the patients (69). Lower PTP1B levels were thus proved to be
associated with poor prognosis and survival prediction of patients (69). Tumor initiating
cells are shown to have lower proliferative potential with higher PTP1B levels (69).
PTP1B levels are also inversely proportional to -catenin nuclear levels (69). Since
Wnt/β-catenin is an important pathway mediating expansion of cancer stem cells, lower
PTP1B levels cause increased tumorigenesis (69). Role of PTP1B in hepatocyte
proliferation has been well studied. Lack of PTP1B activity results in increased EGFR-
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and HGFR-mediated tyrosine phosphorylation, thereby activating Akt and ERK signaling
pathways (70). Increased proliferation of PTP1B deficient hepatocytes and subsequent
delay in termination of liver regeneration is observed in PTP1B null mice (70). This
phenomenon was confirmed by correlation of multiple marker protein levels such as
TGFβ and cyclin D (70). Thus, PTP1B is a strong candidate for developing molecular
therapeutics in obesity, diabetes and cancer management.
A tissue microarray study on 42 HBV or HCV associated HCC samples, followed by
gene expression assay identified PTPN4A3, also called phosphatase of regenerating liver3 (PRL3) in correlation with poorly differentiated tumors, poor prognosis and survival
chance and higher rate of HCC recurrence.(71) Twelve out of 13 hepatoma cells lines
demonstrated lower PRL3 levels, confirming its potential role as a tumor suppressor (71).
Another non-receptor tyrosine phosphatase linked to obesity and cancer is PTPN6 (72).
Heterozygote knockout mice of this gene manifest resistance to high fat diet induced
hepatic stress and insulin resistance (72). Heterozygote PTPN6 liver shows normal
insulin signaling and insulin sensitivity with high fat diet, as opposed to that observed in
wild-type mice (72). Steatohepatitis was also augmented in heterozygote PTPN6 mice,
with comparable cholesterol levels (72). Loss of PTPN6 results in increased activity of
SREBP1 (sterol-regulated element binding protein 1) and other lipogenic enzymes such
as fatty acid synthase (72). Expression of CD36 and FABP5 (Fatty acid binding protein)
increases in PTPN6 knockout mice, and subsequently results in increased hepatic uptake
of fatty acids (72). PTPN6 heterozygote knockouts are also protected against hepatic
inflammation, an important molecular stage allowing transition from steatosis to
carcinogenesis in liver (72). This phenomenon was supplemented by no significant
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increase in inflammatory cytokines IL-3 and IL-6 after 16 weeks of high fat diet (72).
Serum ALT and AST levels were also detected to be within normal range, thus indicating
regular liver function (72). They also demonstrate significantly lower levels of hepatic
gluconeogenesis as compared to the wild-type counterparts (72). PPAR was
overexpressed in primary hepatocytes of PTPN6 knock out mice (72). Global expression
analysis revealed that loss of PTPN6 significantly impacts lipid metabolism, in
accordance with the in vivo observations (72).
Shp2, an intracellular tyrosine phosphatase with Src homology-2 domain containing
protein is encoded by PTPN11. Gain of function mutation in this gene has been observed
in leukemia, establishing this protein as rare PTP oncogene (56). However, recently,
PTPN11 has been implicated as a tumor suppressor in hepatocellular carcinoma (56).
Reduced expression of this protein is also observed in 11.5% of HCC cases (56). Liver
specific knockout of this gene caused increased DEN induced carcinogenesis in mice
(56). This was supplemented by necrosis and infiltration of hepatic tissue with
inflammatory cells, indicated by histological analysis (56). Inflammatory cytokines such
as IL-6 and TNFα were also overexpressed in PTPN11 knock out mice hepatocytes (56).
Splenomegaly and aggravated immunological response to LPS was observed in knock
out mice compared to the wild type mice (56). Spontaneous hepatocellular adenoma
development as a result of sustained STAT3 signaling was observed in knock out mice
(56).
PTPN12 has also been studied as a tumor suppressor in hepatocellular carcinoma. Protein
levels of PTPN12 are inversely correlated to tumorigenesis (73). Decreased PTPN12
levels also correlated with reduced patient survival rate and serum AFP levels (73).
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Clinopathologic analysis established that PTPN12 levels were significant for prognosis in
patients of HCC stage I/II and stage III/IV (73). To further emphasize the role of
PTPN12, researchers proved that decrease in PTPN12 protein levels is concurrent with
increased risk of recurrence and hence, reduced chance of disease free survival (73).
PTPN13 is recently studied as a mir200 target in hepatic tissue. Loss of PTPN13 results
in augmentation of hepatic fibrosis, a key driver of hepatic carcinogenesis (74). These
molecular events are promoted via deregulation of Src signaling cascade in hepatic
fibroblasts (74). PTPN13 protein levels are also down regulated in hepatocellular
carcinoma cell lines, transformed liver fibroblast cell line and 45.8% of HCC tumor
tissues, as compared to normal hepatocytes or corresponding non-tumorous tissue (74).
Accordingly, overexpression of PTPN13 is congruent what increased proliferation.
Reduced expression is a consequence of promoter DNA methylation (74). Genetic
alteration in PTPN13 gene is significantly associated with multiplex familial risk of
hepatocellular carcinoma, strengthening its role as a tumor suppressor gene (74).
Role of PTPN 23 in cancer
PTPN23 gene is located at chromosomal position 3p21.3 and contains 25 exons as
established in the preliminary studies (18). This region is highly susceptible to loss of
heterozygosity mutations in cancer cells (18-20). Multiple mutations within the genes
have been identified, though no single mutations are correlated with a particular type of
cancer or tumor stage so far.
Significance of PTPN23 in neoplasm and cellular transformation was first studied in
cardiomyocytes where it was observed to promote hypertrophy of cardiac tissue (17).
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This group of researchers were first to identify PTPN23 as a potential tumor suppressor.
They observed that Ha-ras mediated foci formation was reduced by more than 3 fold if
cells were transfected with PTPN23 (17). This observation required presence of the
catalytic domain of PTPN23, since the mutant DNA vector, lacking this domain failed to
inhibit cellular transformation (17). Although in vitro tyrosine phosphatase biochemical
assays established that PTPN23 lacked enzymatic activity (17). However, later studies
have identified Src- kinase and Focal adhesion kinase as direct targets dephosphorylated
by PTPN23. Different studies have demonstrated that cellular transfection with PTPN23
DNA promotes anchorage independent cell growth and Ha-Ras mediated transformation
(17).
PTPN23 is also known to inhibit endothelial migration (75). Angiogenesis, an important
hallmark of cancer progression involves migration of endothelial cells from existing
vasculature, into tumorous tissue to form new blood vessels. These endothelial vessels
are essential to maintain high metabolism of cancerous cells. Molecular signaling
cascades leading to endothelial migration as well as angiogenesis are tightly regulated by
coordinated activity of kinases and phosphatases (76). Role of protein tyrosine
phosphatases is emphasized by the fact that PTP inhibitors cause neovascularization in
vitro as well as in vivo (76). This fact was consistent with the observation that knock
down of PTPN23 protein levels in human umbilical vein endothelial cells promoted
migration (75). Cellular phenotype was observed to change from rounded, epithelial to
more taper-ended mesenchymal phenotype, with presence of lamellipodia and
reorganization of actin cytoskeleton (75). Further, this study also established that Focal
Adhesion kinase (FAK) interacts with PTPN23, as indicated by immunoprecipitation
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analysis. FAK is crucial for formation of focal adhesions and is known to manifest
phosphorylation dependent kinase activity (75). Endothelial migration is complimented
by a dynamic, cyclic change in the cytoskeleton mediated by focal adhesion molecules
and stress fibers. PTPN23 knock down was correlated with increased phosphorylation of
FAK and specific localization of this protein, along the plasma membrane to allow
formation of focal adhesions (75). Lack of PTPN23 activity produces results similar to
those observed post 24-hour FGF treatment in these cells. Cells with high PTPN23
protein levels also showed cytoplasmic localization of FAK (75). Bioinformatics analysis
demonstrates structural homology between PTPN23 and Alix/ AIP1, known to interact
with FAK (75). Interestingly, PTPN23 also interacts with Src kinase (25). Src is a nonreceptor kinase, working in conjugation with FAK to modulate turnover of focal
adhesions. An independent study elucidated that PTPN23 regulates phosphorylation of
Src and negatively regulates kinase activity (25). Immunoprecipitation studies confirmed
PTPN23- Src interaction. Alix1, also known to interact with Src shares the biding domain
sequence with PTPN23 (25). Researchers have also demonstrated that augment in
migration of endothelial cells, upon inhibition of PTPN23 is mediated via Src kinase
activity (25). PP2, inhibitor of Src kinase, reverses the scattered, migratory phenotype.
Thus, PTPN23 inhibits Src kinase activity as well as FAK kinase activity, both of which
are essential for membrane localization of FAK and subsequent formation of focal
adhesions. Down regulation of PTPN23 reverses the molecular cascade, allows for FAK
localization and thereby augments cellular motility and migration.
Magnesium is a known chemo attractant for endothelial cells, promoting migration.
Treatment of Human vein endothelial cells (HUVEC) with increasing concentrations of
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magnesium is correlated with reduced migration as well as down regulation of PTPN23
protein levels (77). These results reaffirm the significance role of PTPN23 in endothelial
migration and angiogenesis.
Similar effects in cellular migration have been observed in bladder carcinoma. PTPN23 is
shown to be inversely correlated with cell motility and migration. The research group
confirmed that epidermal growth factor (EGF) not only enhanced interaction between
PTPN23 and Src, but also observed mislocalization of Src within the cytosol in presence
of PTPN23 (78). Src was found to be a key regulator of PTPN23 tyrosine
phosphorylation, which subsequently controlled FAK phosphorylation status and its
localization at focal contacts (78). A more recent finding has shown that loss of PTPN23
function bladder carcinoma is attributed to calcium dependent calpain degradation (79).
The authors have shown that PTPN23 protein levels are in inverse correlation with those
of calcium.
Another interesting observation in context of PTPN23-EGFR interaction was made by
Doyotte et. al. This study demonstrated that loss of PTPN23 inhibits delivery of cell
surface signaling molecule EGFR to lysosomal machinery (26). Significance of
constitutive EGFR signaling is well described in literature. This observation can lead to
the hypothesis that loss of PTPN23 results in deregulation of intra-cellular protein
trafficking and EGFR signaling (25). Subsequently, due to lack of lysosomal degradation
of EGFR, there is an increase in EGFR mediated cell signaling, promoting carcinogensis
(49).
PTPN23 is studied to interact with Grb2 and GrpL proteins (80). These are adapter
proteins belonging to the Grb2 family. It has been established that Grb2 family of
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proteins co-ordinate a multitude of downstream signaling pathways that are relevant in
carcinogenesis, from cell adhesion to invasion and metastasis (81). PTPN23 was found to
be interacting with the adapter proteins via His domain, deduced by yeast two hybrid
screening employing human colon cDNA (80). This finding further strengthens the
evidence, implicating role of PTPN23 in cancer.
A wide scale loss-of-function screening of PTPs in breast cancer cell lines, employing
RNAi-mediated down regulation, identified PTPN23 as a key regulator of cellular
motility and invasion (13). Specifically, down regulation of PTPN23 leads to epithelialmesenchymal transition of cellular phenotype (13). It is concurrent with increased
expression of mesenchymal marker proteins and internalization of E-cadherin (13). These
molecular events are supplemented by marked reduction in cell migration. The study also
affirmed that Src kinase activity was essential to manifest downstream effect of PTPN23
depletion (13). In addition, authors identified β-catenin and E-cadherin as novel
substrates of PTPN23 (13). Authors proposed that loss of PTNP23 in breast cancer cases
might lead to increase Src kinase activity, subsequently causing increased
phosphorylation of β-catenin/E-cadherin complex (13). Phosphorylation status of this
protein complex is crucial in promoting proliferation, growth and invasive properties of
breast cancer cells.
Though chromosomal deletion is a common mode of loss of PTPN23, a recent finding
has suggested potential role of microRNAs and post-transcriptional RNA regulation in
regulating PTPN23 protein levels. Studies in testicular cancer model have demonstrated
that PTPN23 protein levels are negatively correlated with mir142, suggesting PTPN23 as
putative microRNA target (13, 82). Further investigation revealed that PTPN23 functions
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as a tumor suppressor in testicular cancer, inhibits colony formation on soft agar as well
as tumorigenesis in xenografts (82).
In this study, we identified and analyzed SND1-mediated inhibition of PTPN23
expression in hepatocellular carcinoma.
Molecular therapeutic approach
With the advances in research and realization of molecular complexities of human
disorders such as cancer, emphasis is being laid on developing molecular medicine that
shows high specificity and increased efficacy. Molecules with unique structural feature
make it possible to develop specific chemical inhibitors. This approach is especially
critical for oncogenes, inhibiting their expression and downstream signaling. At the same
time, tumor specific over expression of proteins that inhibit carcinogenesis allows
therapeutic application of tumor suppressors via gene therapy. Viral constructs
identifying and targeting strictly cancer cells are available and efforts are made in
employing them for successful clinical trials with several known tumor suppressor genes.
PTPN23, with a strong impact on cellular physiology could potentially be one such tumor
suppressor that could be successfully employed in cancer management. Strategic
chromosomal location, often deleted in human cancers, and literature underlining its
significance in more than one cancer hallmarks, makes this protein a very promising
candidate for gene therapy.
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CHAPTER 3

Identification and Understanding Role of PTPN23 in Hepatocellular
Carcinoma
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INTRODUCTION
SND1 regulates gene expression both at transcriptional and post-transcriptional levels. As
a component of RISC, SND1 mediates RNAi-mediated mRNA degradation (1).
However, SND1 has also been shown to bind to 3’-UTR of specific mRNAs, increase
their stability and hence gene expression. SND1 binds to AT1R mRNA and increases
AT1R mRNA stability (2) and we have shown that activation of AT1R-downstream
signaling by SND1 also plays an important role in the activation of TGF signaling and
EMT (3). We hypothesized that in addition to its RNAi function, SND1 might bind to
additional mRNAs and modulate their half-life, either by increasing stability or directly
degrading these mRNA.

To identify these mRNAs, we chose to perform RNA

immunoprecipitation study using anti-SND1 antibody employing a HCC cell line
expressing high basal level of SND1. RNA sample was amplified and subjected to
sequencing for identification of genes. From a milieu of genes, we chose nine genes that
show 10 fold amplification in SND1 IP as compared to the control IgG IP. After initial
expression screening, we focused on PTPN23 because of its role as a tumor suppressor
(4). We hypothesized that SND1 might bind PTPN23 and degrade it and this
downregulation of PTPN23 by SND1 might contribute to tumor promoting function of
SND1. We also explored the potential role of PTPN23 as a tumor suppressor in HCC
since PTPN23 has not been studied in HCC before. We designed our experiments to
interrogate these questions.
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MATERIALS AND METHODS
1. Cell culture
QGY-7703, Hep3B, Huh 7 and HepG3 human HCC cell lines were cultured in 10%
FBS containing DMEM cell culture media (Life Technologies #12491-015, #11095072), at 37°C in CO2 incubators, under aseptic conditions. Hep3B clones stably
overexpressing SND1 (H-17) and QGY clones with siRNA mediated stable knock
down of SND1 (QGYsh2, QGYsh24) were also cultured under similar conditions (1).
Transient transfection of QGY-7703 was carried out with pcDNA3.1-2Flag-PTPN23
construct. For experimental control, QGY-7703 were also transfected with empty
vector pcDNA3.1, under similar condition. For colony formation assay, 2000 cells
were plated in 6-cm dishes and colonies > 50 cells were counted after 2 weeks
2. RNA- immunoprecipitation and Sequencing
QGY-7703 was employed for immunoprecipitation, using Magna RIP™ RNABinding Protein Immunoprecipitation Kit (Millipore EMD #17-700). Rabbit antiSND1 (Sigma) was used as primary antibody. Extracted RNA sample was amplified
and sequenced to identify target genes. Illumina TruSeq RNA sample preparation kit
was used for preparing RNASeq library, which was sequenced on Illumina
HiSeq2000 platform. RNA-Seq libraries were pooled together to aim about 25-40M
read passed filtered reads per sample. All sequencing reads were aligned with their
reference genome (UCSC human genome hg19) using TopHat2 and the Bam files
from alignment were processed using HTSeq-count to obtain the counts per gene in
all samples. The counts were read into R software using DESeq package and plot

69

distributions were analyzed using Reads Per Kilobase Million (RPKM) values. Data
was filtered based on low count or low RPKM value (<40 percentile). Pairwise tests
were performed between each group using the functions in DESeq. Genes showing
absolute fold-change of >2, False Discovery Rate (FDR) of <0.1 and p-value of <0.01
were selected. Gene cluster analysis was performed using bioinformatics tools for
gene ontology such as KEGG.
3. Tissue microarray
Human HCC tissue microarray from Imgenex (IMH360) was used. For
immunostaining, Rabbit anti-PTPN23 (Sigma Aldrich #HPA016845) was used at a
concentration of 1:100.
4. Immunohistochemistry
Tissue sections of human HCC tumors and corresponding non-neoplastic tissue
sections were obtained from Liver Tissue Cell Distribution System (LTCDS). Rabbit
anti-PTPN23 (Sigma Aldrich #HPA016845) was used at a concentration of 1:100 as
primary antibody. Standard protocol for immunohistochemical staining was followed.
5. Isolation of total RNA, cDNA synthesis, Reverse Transcriptase PCR and qRTPCR
Total RNA was extracted from HCC cell lines or mouse tissues using the miRNAeasy
Mini Kit (QIAGEN). cDNA preparation was done using cDNA Synthesis Kit
(Applied Biosystems). Real-time PCR (RT-PCR) was performed using an ABI ViiA7
fast real-time PCR system and specific TaqMan gene expression assays according to
the manufacturer's protocol. For RT-PCR, gene specific primers, spanning 300-400
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base pair sequence were obtained from Nucleic acid Research Facility (NARF) at
Virginia Commonwealth University. Standard PCR protocol was used.
6. Western blots
Cell lines described above, were lysed in 1.5% DDM lysis buffer. Protein sample was
loaded at a concentration of 50μg/μl on 8% SDS-PAGE gel. Rabbit anti-SND1
(Santacruz Biotechnology Inc. #sc-67128), rabbit anti- PTPN23 (ProteinTech
#10472-1-AP) and mouse anti- GAPDH (Santacruz Biotechnology Inc. #sc-166545)
were used as primary antibodies at 1:1000 concentration, in 5% blocking buffer. AntiRabbit and anti- mouse were used as secondary antibodies, used at 1: 2000 and
1:5000 concentrations, respectively in 5% blocking buffer.
7. Synthesizing radio-labelled 3’UTR-PTPN23 mRNA probe
3’UTR sequence of PTPN23 was amplified by PCR and cloned into pGEMT-easy
vector (according to manufacturer’s protocol) such that target sequence was
transcribed by T7 promoter (Primer sequence: Fwd; 5’ acaggttttgcctacctggtc 3’ and
Rev; 5’ acgggccacagaacagggt 3’). Plasmid was linearized using Sca1 restriction
endonuclease, at 37°C. As a non-specific control, IGFBP-7 pGEMT-easy plasmid
clone was linearized in a similar way. Linearized plasmids were used for in vitro
transcription with T7 Maxiscript kit (Life Technologies # AM1312). In the presence
of radioactive UTP labeled with

32

-P (Perkin Elmer) radiolabelled transcription

products were gel purified on 4% non-denaturing gel and eluted in DEPC water at
37°C.
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8. Binding assay
SND1 protein was synthesized in vitro, employing T7 translation kit (Promega #
L1171). Protein sample was diluted 1:2 in Buffer D (20 mM HEPES, pH 7.0, 0.1 M
NaCl, 3 mM MgCl2, 0.4 mM EDTA, 1 mM DTT, 20% glycerol.). SND1 extract was
incubated with radiolabelled 3’UTR-PTPN23 mRNA, in presence of 10X Binding
buffer (0.1 M HEPES, pH 7.0, 1 M NaCl.). Non-specific radiolabelled probe was
used as control reaction. Reaction was carried out at 4°C for 2 hours.
9. Electrophoretic Mobility Shift Assay (EMSA)
Binding reaction mixtures were analyzed on a 4% non-denaturing gel. Gel was run at
200V for 1-2 hours, at 4°C. Gels were dessicated onto Whatmann’s filter paper and
analyzed by autoradiography.
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RESULTS
1. Identification of target mRNAs interacting with SND1
With strong evidence suggesting SND1 functions as a global regulator of gene
expression, the aim of this study was to identify mRNAs under direct regulation of
SND1. This was aimed to understand molecular changes brought about by SND1 by
modulating gene expression, specific to cancer. For this purpose, we chose to perform
RNA

immunoprecipitation

sequencing

(RIPSeq).

RNA

immunoprecipitation

employing anti-SND1 revealed several target mRNAs to be significantly interacting
with SND1 protein. Out of the total mRNAs sequenced, those with a Read per
KiloBase Million (RPKM) value below 45th percentile were filtered out. RPKM value
was calculated taking into consideration reads per gene and read length. Of the
remaining mRNAs, only those showing significant enrichment in SND1 IP samples
(S1-S5) in comparison to the control IgG IP (C1-C3) were considered for further
analysis. Out of the total mRNAs sequenced, 370 were found to be significantly
enriched in SND1 IP samples, implying putative association of SND1 protein to the
respective mRNA transcripts. It was speculated that SND1 regulates expression of
these genes at post-transcriptional level. Databases such as Gene Ontology
Consortium were employed to identify biological processes that could be potentially
regulated by SND1, depending on the mRNAs identified to interact with this protein.
Critical processes implicated to be under direct SND1 mediated regulation include
RNA processing and splicing, mRNA metabolism, cell junction organization and
assembly, angiogenesis and vasculature development (Figure 3.1, 3.2). Bioinformatic
tools such as KEGG were used for gene clustering and annotation study. Critical
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pathways identified by KEGG analysis included ECM- receptor interactions, focal
adhesion and pathways in cancer (Figure 3.1, 3.2). This data analysis helped us infer
that SND1 affects molecular pathways, via regulation of global gene expression. It
regulates expression of a milieu of genes, transcriptionally as well as posttranscriptionally and affects a variety of cellular processes altered in cancer. Based on
the fold change value, we shortlisted nine genes (Table.1) showing at least a 10 fold
enrichment in SND1 IP as compared to the control IgG IP. These genes were further
analyzed to understand SND1 mediated regulation of the respective transcripts. For
this purpose, mRNA levels of the nine genes were analysed in QGY-7703 cells and
SND1 knock down clone in QGY (QGYsh24), employing Reverse Transcriptase
PCR. Out of the nine genes, three genes (PCSK9, PTPN23, PNPLA7) negatively
correlated and three genes (KCNJ, CELSR2, COL4A2) were in positive correlation
with SND1 protein levels, whereas three genes (BCAM, AGRN, LAMB3) showed no
change in mRNA expression (Figure 3.3). Since PTPN23 mRNA levels are
upregulated in SND1 knock down clones, it was speculated that SND1 negatively
regulates PTPN23 expression. With relevant literature, role of PTPN23 was further
studied in detail with respect to HCC.
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Control IgG Samples

Genes enriched in Control IgG IP

SND1 IP Samples

Genes enriched in SND1 IP

Figure 3.1. Heat Map of RIPSeq data. Heat map indicating the mRNAs enriched in
SND1 IP samples (S1- S5) as well as the control IgG samples (C1- C3). A total of 370
mRNAs were significantly enriched in SND1 IP samples in comparison to the IgG IP
sample. These mRNAs were then filtered based on fold change to shortlist few mRNAs
significantly interacting with SND1.
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Figure 3.2 Biological Processes and pathways potentially regulated by SND1.
mRNAs enriched in SND1 IP samples were found to be significantly involved in above
mentioned biological processes, as studied using Gene Ontology Consortium database.
KEGG analysis was used to identify major pathways in which the enriched 370 mRNAs
were playing an important role. The listed pathways are potentially regulated by SND1,
as indicated by KEGG analysis of sequencing data.
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Gene Id Control mean SND1 IP mean

Fold
Enrichment

P- value

Protein Function

BCAM

84.99

1426.40

16.78

1.73E-65

Cell adhesion

PCSK9

2.13

34.94

16.39

1.14E-09

Cholesterol
homeostasis

AGRN

695.054

8559.479

12.314

2.21E-31

Cell – ECM
interaction

KCNJ12

5.0861

58.448

11.491

9.43E-14

Senescence

PNPLA7

2.274

24.514

10.777

1.17E-05

Lipid metabolism

CELSR2

252.998

2604.322

10.293

1.60E-69

Circulating Lipid
Levels

COL4A2

211.599

2141.286

10.119

6.18E-38

Metastasis

LAMB3

446.552

4520.898

10.124

1.30E-108

Cell adhesion

PTPN23

313.245

3144.123

10.037

1.56E-114 Migration/ Invasion

Table 1. A shortlist of nine mRNAs regulated by SND1. A list of nine mRNAs were
shortlisted on the basis of fold change (>10 value) and significance level, for preliminary
in vitro screening. Identified mRNAs were speculated to be under SND1 mediated posttranscriptional regulation.
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Figure 3.3. SND1 differentially regulates each of the nine mRNAs. Reverse
Transcriptase PCR analysis was performed on RNA sample obtained from QGY-7703 cells
and SND1 knockdown clones of QGY-7703 (QGYsh24) Primers spanning 300-400 bp
region of each of the nine shortlisted genes were synthesized and used for PCR. LAMB3,
AGRN and BCAM showed equal mRNA levels in QGY cells and knock down clones
whereas KCNJ, CELSR2 and COL4A2 were downregulated in SND1 knockdown clones.
PCSK9, PTPN23 and PNPLA7 mRNA levels were upregulated in SND1 knockdown
clones.

2. PTPN23 is down regulated in HCC
With preliminary studies indicating downregulation of PTPN23 expression in HCC
and thus suggesting a tumor suppressive function of this protein, it was important to
observe PTPN23 expression pattern in HCC. Immunohistochemical analysis of
PTPN23 expression was performed on a tissue microarray (Imgenex) of 38
hepatocellular carcinoma, 2 cholangiocarcinoma, 10 metastatic hepatocellular
carcinoma and 9 corresponding non-neoplastic liver tissue samples. Approximately
40% of these cases demonstrated down regulation of PTPN23 levels (Figure 3.4).
Immunohistochemical staining was also performed on human HCC sections with
adjacent non-neoplastic tissue. Loss of PTPN23 expression was specific to neoplastic,
highly proliferative tissue. PTPN23 expression was also corelated with SND1 protein
levels in HCC cell lines, at mRNA as well as protein level. SND1 knockdown clones
in QGY-7703 cell line showed higher PTPN23 mRNA as well as protein expression,
in comparison to parental cell line (Figure 3.5a). SND1 knock down correlated with
up to 3 fold increase in PTPN23 transcript level in comparison with parental QGY7703 cells (Figure 3.5a) SND1 over-expressing clone (H17) in Hep3B cell line did
not show significant decrease at mRNA level, though a marked reduction in PTPN23
protein was observed (Figure 3.5a-b). Overall, PTPN23 mRNA levels were observed
to be lower in HCC cell lines Huh-7, HepG3 and QGY-7703 in comparison to normal
hepatocytes (Figure 3.5a). Thus, SND1 protein levels negatively correlated with
PTPN23 expression in HCC, at transcriptional as well as post-transcriptional level.
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Figure 3.4 HCC tissue microarray. Immunohistochemical staining of a HCC
tissue microarray was performed. Loss of PTPN23 protein expression was
observed specifically in HCC tissue sections and compared to normal nonneoplastic tissue sections
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Figure 3.5 SND1 protein levels negatively correlate with PTPN23 expression (a):
Quantitative Real Time PCR analysis showed up to 2-fold decrease in PTPN23 transcript
levels in human HCC cell lines (HepG3, Huh7, QGY, Hep3B) in comparison to normal
human hepatocytes. SND1 knockdown clones (QGYsh2, QGYsh24) in QGY-7703 cells
showed up to 3-fold increase in PTPN23 transcript levels in comparison to parental
QGY-7703 cells. Not a significant difference is observed in PTPN23 transcript levels in
SND1 over expressing clones (H17) and parental Hep3B cells.
Figure 3.5 (b): Western Blot analysis showed upregulation of PTPN23 protein expression
in SND1 knockdown clones (QGYsh2, QGYsh24). PTPN23 protein levels were
significantly reduced in SND1 overexpressing clone (H17) in comparison to parental
Hep3B cell line.
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2. PTPN23 inhibits cell proliferation in HCC cells
Since tyrosine phosphorylation dependent signaling is heavily implicated in cell
proliferation and growth, it was hypothesized that PTPN23 regulates this cellular
function. For this purpose, we performed colony formation assay in cells
overexpressing PTPN23. QGY-7703 cells were transfected with pcDNA3.1-FlagPTPN23 construct. Cellular proliferation as measured by Colony formation assay
showed more than 90% decrease in the number of colonies formed by QGY-7703
overexpressing PTPN23, as compared to control QGY-7703 cells (Figure 3.6). Thus
it can be inferred that over expression of PTPN23 in cancer cells might inhibit tumor
growth in vivo, in HCC.
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Figure 3.6 Overexpression of PTPN23 inhibits cellular proliferation in HCC. QGYFigure 4: PTPN23 overexpression in HCC cell line reduces p
7703 cells were transiently transfected with PTPN23 pcDNA3.1 construct and empty
vector pcDNA3.1 as control. Colony formation assay was performed with transiently
transfected cells. PTPN23 overexpressing cells showed more than 90% reduction in
colony formation.
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3. SND1 protein binds to PTPN23 mRNA
Since RIPSeq does not affirm direct protein-RNA interaction and relevant literature
indicating this interaction as a potential regulatory mechanism, it was necessary to
observe SND1 and PTPN23 mRNA interaction in vitro. We performed an in vitro
binding assay with SND1 protein and 32-P labelled 3’UTR of PTPN23 mRNA, the
results of which were analyzed using EMSA. This was aimed to help us understand
how SND1 suppresses PTPN23 expression in HCC. Using T7 MaxiScript kit,
radiolabelled 3’UTR PTPN23 mRNA was synthesized in vitro. The RNA probe was
gel purified and utilized for subsequent binding assay. SND1 protein was also
synthesized in vitro with T7 translation kit. Binding reaction was carried out at 4°C
for 2 hours and the reaction mixture was analyzed by electrophoretic mobility shift
assay. A shift in band position was observed when SND1 was incubated with 3’UTR
PTPN23 (Figure 3.7). Furthermore, when reaction mixture was incubated at 37°C, no
corresponding band was observed, indicating absence of radiolabelled mRNA,
possibly due to SND1 mediated degradation (Data not shown). For further confirming
specificity of SND1 protein binding to the 3’UTR mRNA sequence, binding
reactions were subjected to RNase treatment at 37°C for 15 minutes and the samples
were analyzed by EMSA. IGFBP7 transcript was not observed, whereas a clear band
of 3’UTR transcript was seen by autoradiography (Data not shown). It was inferred
that SND1 binds to the 3’UTR and therefore offers protection against RNase
degradation. Thus, it can be hypothesized that SND1 binds to PTPN23 transcript at
3’UTR and possibly degrades it under physiological conditions, causing down
regulation of protein.
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3’UTR mRNA + SND1

3’UTR mRNA

PTPN23 mRNA

3’UTR mRNA

3’ UTR + SND1

IGFBP7 mRNA + SND1

IGFBP7 mRNA

Figure 3.7. SND1 binds to 3’UTR of PTPN23 mRNA. 32-P radiolabeled mRNA probes
spanning 3’UTR of PTPN23 and IGFBP7 full length transcript (as positive control) were
incubated with in vitro translated SND1 protein, at 4°C. Electrophoretic Mobility Shift
Assay demonstrated a supershift in band position when 3’UTR of PTPN23 is incubated
with SND1 protein, indicating a protein – mRNA interaction.
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CHAPTER 4
Discussion and Future perspectives
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DISCUSSION
Staphylococcal Nuclease Domain containing protein 1 (SND1) is crucial mediator of
molecular events that culminate into carcinogenesis. Role of SND1 has been studied
in multiple cancers as an oncogene, promoting proliferation, invasion, angiogenesis
and EMT (5-9). In reference to hepatocellular carcinoma, we have previously
demonstrated that SND1 promotes tumorigenesis using both in vitro assays as well as
nude mice xenograft models (1, 3, 10). It was also established that functional role of
SND1 in RNA induced silencing complex (RISC) is one of the critical mechanisms
via which this protein regulates global gene expression (1). Specifically, we observed
that SND1 down regulates expression of tumor suppressor genes such PTEN via
RISC activity employing miR-221(1). There are several reports elucidating role of
SND1 in regulation of gene expression at transcriptional and post-transcriptional level
(2, 11, 12). Since SND1 shows RNA binding as well as differentially regulates
expression of multiple genes employing a diverse array of functions, we were
interested in identifying target mRNAs that are modulated by SND1 interaction, at a
post-transcriptional level. The rationale was to understand SND1 mediated changes in
gene expression and subsequent molecular pathways, in reference to cancer and
inflammation. We employed RIPSeq approach for this aim and observed a vast
number of mRNAs potentially interacting with SND1. In accordance to our
hypothesis, RIP-Seq data identified multiple SND1 interacting mRNAs, mostly
affecting RNA processing and splicing, mRNA metabolism, cell junction assembly
and morphology, cell cycle and division, replication, vasculature development and
angiogensis. The relevance of these pathways in tumor development, cell cycle and
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signaling further confirms the notion that SND1 mediates dynamic changes at
molecular level, affecting cellular physiology. Such changes in global molecular
signaling are key to development of cancer and hepatocellular carcinoma, in
particular. It should be noted that the mRNAs identified in RIPSeq data are
speculated to potentially interact with SND1 protein. However, the effect of posttranscriptional regulation by SND1 on each of them is independent and needs to be
studied individually, in vitro.
We selected nine genes with a fold change value >10 and functional relevance for
further in vitro analysis. Since SND1 is known to specifically down regulate or
upregulate gene expression, it was necessary to understand SND1 mediated
regulation of these nine genes. Expression pattern of these mRNAs were analyzed in
correlation to SND1 protein levels, by Reverse Transcriptase PCR using QGY-7703
and SND1 knock down clone (QGYsh24). As expected, all nine mRNAs were found
differentially correlate with SND1 protein levels. Three out of nine genes were up
regulated whereas three were down regulated in SND1 knock down clones.
Remaining three genes showed no change in expression in correlation to SND1
levels. This observation affirms the theory that SND1 modulates gene expression by
more than one mechanism. There have been reports indicating increased mRNA
translation conferred by stabilization of the transcript by SND1 protein. We observed
that PNPLA, PCSK9 and PTPN23 are up regulated when SND1 is knocked down in
QGY-7703 cells. Down regulation of CELSR, COL4A2 and KCNJ was correlated
with low SND1 protein levels in knock down clones. This varied observation can be
attributed to nuclease activity or increased mRNA stabilization and translation by
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SND1. PNPLA7 is a phospholipase whereas PCSK9 is known to plays a crucial role
in cholesterol homeostasis. It degrades LDL receptor expression, thus reducing
cellular intake of LDL. SND1 mediated down regulation of PCSK9 is thus, in
agreement with increased lipid uptake of hepatocytes, a condition characterized as
steatosis that initiates inflammation and leads to carcinogensis. PCSK9 is currently
being pursued as a potential molecular target for familial hypercholesterolaemia (13).
CELSR2 is identified in a genome- wide meta-analysis study, to be significantly
associated with increased risk for coronary artery disease and influencing circulating
lipid levels (14). These findings suggest that SND1 might be a regulator of
cholesterol metabolism. COL4A2 expression is altered and significantly associated
with metastasis in laryngeal cancer (15). In epithelial ovarian cancer cells, COL4A2
upregulation mediates anoikis resistence (16). Interestingly, three genes BCAM,
AGRN and LAMB3 did not show a difference in expression levels upon SND1 knock
down. Detailed mechanistic analysis will help understand the role of SND1 in
regulating the identified genes in the context of their functional pathways. It is also
with relevant literature supporting its role as tumor suppressor, was the highlight of
this study (4, 17, 18). PTPN23 is so far implicated as a potential tumor suppressor in
breast cancer, where it regulates invasion (18) and testicular cancer, where it’s
expression is lost as result of miR142-3p mediated degradation (17). Preliminary
investigation in HCC tumor samples by immunohistochemical approach reveal that
PTPN23 expression is lost in HCC liver sections in comparison to non-neoplastic
normal liver sections. Further analysis proved that SND1 protein levels negatively
correlate with PTPN23 expression, at a transcriptional as well as post-transcriptional
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level. According to the results observed, one of the possibilities is that SND1
represses transcription of PTPN23 as a co-repressor protein. Hence, in SND1 knock
down clones (QGYsh2, QGYsh24) we observe a 3 fold induction in PTPN23
transcript levels. An independent mode of regulation would be inhibition of
translation of the PTPN23 mRNA. This possibility would explain the lack of
difference in PTPN23 mRNA levels in SND1 overexpressing clones (H17) but a
significant reduction in protein levels of the same clone. Although it is very critical to
confirm the qRT-PCR analysis of PTPN23 mRNA levels in SND1 overexpressing
clone (H17) and rule out any discrepancy. Especially since in subsequent experiment
we find compelling evidence that SND1 might be degrading PTPN23 transcript, and
this could also be a potential underlying mechanism of downregulation of PTPN23
protein in SND1 overexpressing (H17) cells.
Loss of 3p21.3 chromosomal location, housing PTPN23 gene has been associated
with multiple cancers (19-21). Tissue microarray data, analyzing PTPN23 expression
in normal and neoplastic liver tissue sections from HCC patients, helped in
strengthening the tumor suppressive role of PTPN23. A marked decrease in PTPN23
protein was observed in tumor tissue as compared to adjacent normal tissue.
Although, there was no correlation between PTPN23 protein expression and
progression of HCC stages and metastasis.
Accordingly, overexpression of PTPN23 protein in a highly aggressive HCC cell line
(QGY-7703) resulted in severe decrease in cellular proliferation. However, these
results need to be confirmed in clones with inducible expression of PTPN23 and
eventually in an in vivo model. Forced overexpression of PTPN23 causes severe cell
90

death (data not shown), emphasizing the necessity to establish inducible clones,
which can be employed for long term in vitro studies. The exact mechanism,
underlying reduction in proliferation remains to be studied. It will be interesting to
understand whether this observation is result of increase in apoptosis or decrease in
replicative potential of cells. Such studies shall be instrumental in understanding the
molecular pathways under regulation of phosphatase activity of PTPN23.
In this study, we were successful in establishing the SND1- PTPN23 interaction in
vitro. According to the observation by EMSA, in vitro translated SND1 protein binds
to 3’UTR region of PTPN23 mRNA at 4°C, under conducive conditions. This
binding interaction between SND1 and 3’UTR of PTPN23 transcript was observed to
be a specific event and presumed to lead to mRNA degradation. This assumption was
based on the observation that the binding reaction mixture comprising of SND1 and
3’UTR-PTPN23 transcript, incubated at 37°C, for 2 hours, showed no band in
EMSA analysis (data not shown).
Studies so far have deduced that this phosphatase interacts with critical kinases such
as Src and Focal Adhesion kinase (FAK) to inhibit cellular migration (22, 23). Initial
studies have confirmed decrease in Ha-Ras mediated cellular transformation and
proliferation, upon over expression of PTPN23 (4). There is also strong evidence
implicating role of PTPN23 in endothelial migration regulating angiogenesis,
migration of cancer cell lines as well as inhibition of invasion in breast cancer
patients (24). These studies, emphasizing role of PTPN23 in manifesting hallmarks of
cancer, indicate that reviving PTPN23 expression in cancer cells specifically, should
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ameliorate disease condition. PTPN23 expression is expected to manifest as a
protective mechanism against tumorigenesis in in vivo mice model.
Employing SND1 as a therapeutic target is at a risk of affecting global molecular
networks, with increased chances of unfavourable downstream effects. However, it
seems interesting to target SND1 specifically within tumor cells, and subsequent
reduction in carcinogenesis. With a unique Tudor-SN fusion protein domain,
specificity and high efficacy drug targeting is not a far reaching goal. Loss of SND1,
an anti-apoptotic protein is expected to induce wide scale cellular death. It should also
allow up regulation of tumor suppressors, which subsequently induces cell death. If
targeted restrictively to cancer cells, SND1 is a very promising candidate in
molecular drug development.
Alternatively, specific relevant downstream targets of SND1 would be potential
molecular therapy candidate genes. Due to high significance studies proving role of
PTPN23 as a tumor suppressor gene, testing its therapeutic potential on liver specific
SND1 transgenic model or a xenograft study with adeno-associated viral construct of
PTPN23 seems promising.
According to current findings, SND1 and PTPN23 are crucial for HCC development
as well as progression. Pursuing detailed studies on understanding function of
PTPN23 in cancer, specifically HCC, employing in vitro studies with stable clones
and eventually an in vivo model, would be an interesting future direction.
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CONCLUSION AND FUTURE DIRECTION
SND1 is known to orchestrate a series of changes that affect global gene expression
and brings about cellular transformation. It regulates gene expression employing
multiple unique mechanisms that function at transcriptional as well as posttranscriptional level. With increasing relevance of studies on SND1 in the context of
carcinogenesis it is important to elucidate the molecular mechanisms underlying
SND1 activity. Studies so far suggest it is a promising molecule for clinical
investigation and targeted therapeutic management of cancer. Considering the
pleiotrophic functions of SND1, one important question that has not been addressed is
that how important is SND1 for maintaining normal physiological function including
growth and development. An SND1 knockout mouse, conditional and global, will not
only provide comprehensive insights into the physiological functions of SND1 but
also will be an ideal model to interrogate the role of SND1 in immortalization,
transformation, metastasis and overall cancer development and progression.
Conversely, organ-specific SND1 transgenic mouse will also provide useful insight
into the oncogenic function of overexpressed SND1. Is SND1 overexpression alone
sufficient for transforming normal cells into cancer cells? Can SND1 function as a
driver for tumorigenesis or is it a promoter following initial mutagenic events? Which
particular aspects of SND1 function are most relevant to confer its oncogenic
properties? Future studies need to be focused toward these angles.
PTPN23 is a potential discovery that can be pursued for gene therapeutics. Inducing
PTPN23 expression in cancer cell specific manner is expected to inhibit
tumorigenesis by reducing cell proliferation, migration and increasing apoptosis.
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Whether these in vitro findings remain true under in vivo conditions needs to be
elucidated by over expression of PTPN23 in a HCC mice model. Though
embryological expression patterns of PTPN23 have been elucidated, its role in
maintenance of normal physiology is not known. Hence, a global knock out or liver
specific knock out of this gene will illustrate its role in maintaining normal
physiology as well as its tumor suppressor functions. Very little is known so far about
this protein in normal hepatic physiology, and it would be an imminent question to be
answered before employing this protein in molecular medicine. First and foremost,
we need to understand the signaling pathways that are under direct regulation of
PTPN23. For this purpose, it is necessary to identify the phosphorylated tyrosine
substrates of the phosphatase activity of this protein.
Another important discovery in this study is PCSK9, a known regulator of plasma
LDL levels. PCSK9 is known to bind to LDL receptors, mediate their degradation by
endocytosis thereby causing hypocatabolism of cholesterol in liver and increased
levels of circulating LDL. Decreased PCSK9 levels correlate with increase in LDLR
activity and subsequent increase in uptake of LDL in human hepatocytes, such as
HepG2 and Huh7 (25, 26). Such an increased uptake of LDL within hepatocytes leads
to hepatosteatosis, which is expected to initiate inflammatory response that progresses
to HCC. Currently, PCSK9 is also being employed for therapeutic targeting for
developing therapies against familial hypercholesterolaemia (13). Since steatosis
induced cirrhosis is one of the major conditions causing HCC development, it would
be interesting to study SND1 mediated down regulation of PCSK9 and subsequent
impact on hepatic physiology.
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There are several other mRNAs identified in RIPSeq analysis, which are implicated
in lipid metabolism and cholesterol homeostasis, affirming that SND1 might be
closely regulating these biological processes.
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